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Preface 
 
This dissertation contains five chapters covering my investigations on three key biosynthetic 
steps involved in the formation of the bicyclo[2.2.2]diazaoctane compounds. Chapter 1 begins 
with an introduction to natural products and particular the fungal indole alkaloids, which were 
the focus of my dissertational work. Chapter 2 is an adaptation of a submitted manuscript titled 
“Substrate Controlled Flavin Monooxygenases Reveal Strategy for Fungal Indole Alkaloid 
Structural Diversification,” for which I am first author. This manuscript was prepared for 
submission to the Journal of the American Chemical Society for peer review during the 
completion of my dissertational work, and it focuses on the flavin monooxygenases NotI, NotI′ 
and PhqK. Chapter 3 focuses on my extensive work covering the prenyltransferase MalE from 
the malbrancheamide biosynthetic pathway. In this chapter I describe our attempts at discovering 
Diels-Alder biosynthetic activity and how investigations will be continued in the laboratory 
following the completion of my Ph.D. Chapter 4 summarizes our investigation of the MalA 
halogenase from the malbrancheamide pathway. This work is currently being prepared for 
submission to a peer-reviewed journal. Finally, I discuss potential future directions in Chapter 5 
based on the findings in my dissertational research.
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Abstract 
 
Comparative Investigation of Key Biosynthetic Transformations in Fungal Indole Alkaloid 
Natural Product Pathways 
by 
Hong T. Tran 
 
Chair: David H. Sherman 
My dissertational research has focused on the elucidation of three key biosynthetic steps 
involved in the formation of fungal indole alkaloid natural products. Beginning with the 
comparative analysis of four assembled putative gene clusters, we performed a detailed 
annotation of the predicted gene functions and proposed a biosynthetic pathway for each 
compound: (+)-notoamide, (-)-notoamide, malbrancheamide, and paraherquamide. Although 
these molecules have demonstrated interest in biological activity and intriguing chemical 
synthesis, our understanding of their biosynthesis has been limited. Therefore, we sought a 
stronger biochemical understanding of the biosynthetic enzymes involved in the formation of 
these molecules. Additionally, an intriguing intramolecular Diels-Alder mechanism is expected 
to occur in the biosyntheses of these bicyclo[2.2.2]diazaoctanes. Although the Diels-Alder 
reaction has been predicted to be involved in the formation of many natural products, the 
biochemical mechanism has remained fairly elusive and thus has been a topic of intense debate 
within the field.  
Firstly, NotI, NotI′, and PhqK were identified as flavin monooxygenases from the notoamide 
and paraherquamide gene clusters. These enzymes catalyze an epoxidation followed by 
semipinacol rearrangement to generate the spirooxindole moiety found in this class of 
compounds. Additionally, their utility as tools in synthetic biology was demonstrated by the wide 
range of flexibility of substrates accepted by these enzymes to broaden the pool of chemical 
diversity, yielding a new metabolite named notoamide T9. However, further efforts to optimize 
the catalytic activities of these enzymes is likely necessary in order to develop an effective 
approach to extend structural diversification of the bicyclo[2.2.2]diazaoctanes.  
  
xix 
 
Second, we pursued a thorough biochemical investigation of the MalE prenyltransferase as 
the primary candidate for the intramolecular Diels-Alder reaction in the malbrancheamide 
biosynthetic pathway. Early experiments demonstrated the ability of MalE to reverse prenylate 
early intermediate dipeptides. However, reactions containing the putative native substrate led to 
the conclusion that MalE is a capable reverse prenyltransferase, but it does not seemingly 
perform the intramolecular Diels-Alder reaction. Interestingly, the lack of cyclization to form the 
Diels-Alder product supports the prediction that a biocatalyst is needed to facilitate the reaction 
within the biosynthetic system.  
Finally, we investigated the halogenase MalA from the malbrancheamide pathway as an 
alternate candidate for the Diels-Alder reaction. The enzyme demonstrated catalytic activity and 
performed a halogenation event as predicted. However, contrary to expectations, the enzyme is 
only able to perform the second halogenation to form the final metabolite malbrancheamide, 
rather than the initial halogenation on premalbrancheamide. Interestingly, we were also able to 
generate new metabolites with mixed halogen substituents named malbrancheamide D and 
isomalbrancheamide D.  
In summary, we elucidated three key steps in bicyclo[2.2.2]diazaoctane biosynthesis. These 
studies contribute directly to the understanding of complex fungal biosynthetic enzymes and the 
transformations they catalyze. Furthermore, these enzymes have demonstrated utility in 
diversification of chemical structures in this family of compounds, and thus have implications in 
their use as biocatalysts.  
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Figure 1-1. Sources of natural products. (Left) Chinese herbal remedies. (Center) The willow tree, the source of 
salicylic acid and aspirin. (Right) Penicillium fungus from which penicillin was isolated. 
 
 
 
 
 
Chapter 1 
1 Introduction to fungal indole alkaloid natural products 
 
1.1 Natural products are a rich source of bioactive molecules with interesting chemistry 
 
Long ago, before we began to call these compounds “natural products,” herbalists had been 
collecting and identifying plants that could be used to treat ailments and disease. Herbal 
medicine can be collected from the various parts of the plant: seeds, roots, berries, etc., and are 
often used to treat disease or increase the vitality of the patient.
1
 Even in my own life, I was 
raised by parents who purchased and used eastern remedies to treat illness. Today, although we 
no longer rely exclusively on herbal medicines to treat pain or disease, we still use the active 
ingredients contained within those sources that have been identified and produced for 
consumption. Aspirin, for example, was developed from salicylic acid collected from the willow 
tree, which was known to provide relief from pain since its historical use by the Babylonians.
2
 
Penicillin, another well-known natural product, was initially identified in the 1920s and gave 
way to the beginning of the antibiotic age. Since then, a class of antibiotics derived from 
  
2 
 
penicillin has been developed to treat pneumococcal, streptococcal, meningococcal, and 
gonococcal infections.
3
 This process of developing medicine from an identified lead compound 
isolated from a natural source drives much of our pharmaceutical industry today.
4
 Based on these 
criteria, natural products (NPs) have accounted for approximately 47% of the new drug 
discoveries in the past 25 years.
5
   
 Eukaryotes, particularly plants and fungi, have long been a source of unique and effective 
natural products, although their potential as a resource for NP discovery is frequently 
understated.
6
 High environmental stress, along with an impressive ability to absorb nutrients 
from the soil or decomposing material, drives the incorporation of foreign chemical components 
into product formation.
7
 While these complex interactions between the environment and the 
producing organism may produce useful and unique NPs, they also contribute to the difficulty of 
investigating or replicating the production of these organisms within a laboratory setting. 
Another example of an important therapeutic derived from plants is taxol, an important 
anticancer agent discovered in the 1970s. Taxol is isolated from the bark of yew and unmodified 
when sold to the consumer.
8
 The story of taxol presents an interesting case, where the producing 
organism Taxus brevifolia is an endangered species but the most reliable source of the low 
toxicity, broad-spectrum anticancer agent.
9
 It is from this impending crisis that the motivation 
arose to find alternative approaches to obtaining precious materials like taxol. The need for 
alternative approaches to developing useful medications, along with the desire to generate new 
and interesting bioactive molecules, drives our motivation to understand the biosynthesis of these 
unique NPs within their producing organisms. 
1.2 Fungal indole alkaloids comprise a class of natural products 
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The class of fungal indole alkaloids includes primarily the prenylated indole alkaloids and ergot 
alkaloids.
10,11
 The prenylated indole alkaloids, as is suggested by their name, are characterized by 
two main components: an indole ring (usually tryptophan) that is modified by prenyltransferase 
enzymes to install isoprene units on the molecule.
12
  Ergot alkaloids, on the other hand, are 
formed from a tryptophan moiety that has been prenylated before undergoing a series of 
oxidation reactions to form their characteristic tetracyclic ergoline ring.
13
 The compounds are 
typically produced by Penicillium or Aspergillus strains and can be either terrestrial or marine in 
origin.
10
 Occasionally, the compounds will also be found in organisms in different domains of 
life. Lyngbyatoxin and Hapalindole H, for example, are produced by cyanobacteria,
14,15
 and the 
flustramines are isolated from a bryozoan.
16
 
One of the largest groups within the fungal indole alkaloids is the group of prenylated 
derivatives constructed from L-proline and L-tryptophan.
12
 The group includes the insecticidal 
brevianamides and sclerotiamides, anthelmintic paraherquamides, calmodulin-inhibitory 
 
Figure 1-2. Examples of prenylated fungal indole alkaloids, their producing organisms, and their biological 
activities (if known). 
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malbrancheamides, mycotoxin fumitremorgin, anticancer notoamides, stephacidins, and 
citrinadins, among others.
17–21
 This class of compounds depicts a wide variability in biological 
activities, along with a diversity in chemical structures of the final compounds. Brevianamide F, 
the dipeptide fusion of proline and tryptophan, is the most common precursor to the formation of 
the majority of these molecules and is thus presumed to be an intermediate in the formation of 
aforementioned natural products.
22
 
One class of prenylated fungal alkaloids are the bicyclo[2.2.2]diazaoctanes, a family of 
compounds typified by their unique core (Figure 1-3).
23
 The members of the 
bicyclo[2.2.2]diazaoctane alkaloid family demonstrate various desirable biological activities 
from anti-parisitic to anti-cancer, despite sharing the same core structure.
24,25
 We have been 
interested in the biosynthesis of these molecules not only for their pharmacological activities but 
also for their unique and complex chemistry. Extensive efforts have been put forth by the 
Williams group to synthesize these molecules in their entirety.
26
 In particular, the formation of 
the bicyclo[2.2.2]diazaoctane ring system is expected to occur via an intramolecular Diels-Alder 
(IMDA) reaction as initially proposed in 1970 by Sammes and Birch.
27
 While the reaction was 
initially performed using an intramolecular SN2′ cyclization,
28
 later applications of a biomimetic 
Diels-Alder reaction have shown that the approach is a reasonable method for obtaining the 
bicyclo ring system, reinforcing the hypothesis that a biosynthetic Diels-Alder enzyme could 
exist in nature.
29
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Figure 1-3. Depiction of the bicyclo[2.2.2]diazaoctane core that 
defines this class of fungal indole alkaloids. 
 
Along with the formation of the bicyclo[2.2.2]diazaoctane core, the various compounds 
within the family each bring with them a unique and rare set of biosynthetic origins and often 
potent bioactivities. An intriguing story of enantioselective biosynthesis can be found in the 
notoamides, where a terrestrial fungus produces one set of enantiomers while a marine fungus 
produces the opposite set.
30
 The fumitremorgins are a tremorgenic group of mycotoxins that have 
also recently demonstrated possible utility as an anticancer agent.
18,31
 The malbrancheamides add 
halogen substituents to further diversify the chemistry found in these molecules.
17
 Other 
examples include the stephacidins,
32
 paraherquamides,
33
 sclerotiamides,
20
 and brevianamides.
27
 
Additionally, the bicyclo[2.2.2]diazaoctanes can be divided into two major categories: the 
monooxopiperazines and the diooxopiperazines (Figure 1-3). These compounds have 
demonstrated biological interest as potential anticancer agents and anthelmintic treatments, 
among others, and unexpectedly manage to do so despite sharing the same bicyclo core. That the 
same core molecule is produced by so many different organisms from so many different origins 
in nature is in and of itself a complex and fascinating story in the evolution of these biosynthetic 
gene clusters. Perhaps diversification was brought about by tailoring steps introduced or 
removed from the central gene cluster throughout many generations of fungi carried from one 
continent to another.  
1.3 The Notoamides 
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The notoamides were discovered in 2007 from a marine derived fungus, Aspergillus protuberus 
(formerly known as Aspergillus MF297-2), which was isolated from the mussel Mytilus edulis 
collected off the Noto Peninsula of Japan by the Tsukamoto group.
34
 These compounds added to 
the already existing library of bicyclo[2.2.2]diazaoctane fungal alkaloids, then including the 
stephacidins and paraherquamides. The notoamides were discovered during an extensive search 
for compounds that exhibited interesting pharmacological activities,
35–38
 and particularly during 
a screen for cytotoxic activity and possible use as anticancer agents. Since their original 
discovery in 2007, the notoamides have since seen an extensive expansion in the number of 
related metabolites,
39–41
 stretching today from molecules A through V (see Chapter 2). 
 In addition to the isolation of new notoamide compounds, extensive synthetic approaches 
have been performed by the Williams laboratory. Among them, key chemical transformations 
were addressed using biomimetic syntheses. The first investigation addressed the formation of 
the spirooxindole ring system via a pinacol rearrangement, resulting in the synthesis of 
notoamides C and D.
42
 The synthesis of notoamide J similarly addressed the formation of an 
intermediate via a pinacol rearrangement.
43
 Notoamide S has been recently synthesized as a 
means to obtain an important, pivotal intermediate as the final common precursor between A. 
amoenus and A. protuberus before enantio-divergence.
44
 Racemic stephacidin A was also 
synthesized, and in the process added to the desire to understand how the Aspergillus strains 
controlled the enantiomeric divergence presented by the notoamide group of compounds.
45
  
 The biomimetic syntheses were important to the understanding of the biosynthetic 
pathways that drive the formation of notoamide, but they also provided an approach to obtaining 
compounds for isotopically enriched precursor incorporation studies. Extensive collaborative 
efforts have since been put forth by the Sherman, Williams, and Tsukamoto laboratories to test 
  
7 
 
Table 1-1. Comparison of amino acid sequences of Not and NotI´ and description of the putative function of 
each gene. 
Not proteins 
A. protuberus 
(AA) 
Not’ proteins 
A. amoenus 
(AA) 
Putative Function (% AA identity) 
NotA (339) NotA’ (334) Negative regulator 70%  
NotB (456) NotB’ (455) FAD monooxygenase 88%  
NotC (427) NotC’ (426) Prenyltransferase 87%  
NotD (621) NotD’ (612) Oxidoreductase 80%  
NotE (2241) NotE’ (2225) NRPS [A-T-C-A-T-C] 79%  
NotF (453) NotF’ (435) Prenyltransferase 79%  
NotG (544) NotG’ (544) P450 monooxygenase 87%  
NotH (502) NotH’ (499) P450 monooxygenase 84%  
NotI (434) NotI’ (433) FAD monooxygenase 85%  
NotJ (371) NotJ’ (362) Unknown 80%  
 
 
the incorporation of these molecules into the producing organisms. Upon feeding isotopically 
labeled stephacidin A precursor to the A. amoenus and A. protuberus producing organisms, the 
compound was found to be incorporated into notoamide B and sclerotiamide, indicating that both 
metabolites can be formed downstream of intermediate stephacidin A.
45
 Notoamide T was also 
synthesized with isotopic labeling, and incorporation studies showed that the compound could be 
incorporated into stephacidin A and notoamide B, while synthetic approaches also showed 
possible formation of 6-epi-stephacidin A.
46
 
As we arrived closer to an understanding of the biosynthetic steps involved in the 
generation of the notoamide compounds, we still lacked biochemical evidence to support the 
steps we had proposed. Thus, the collaboration began a thorough and detailed bioinformatic 
analysis of the gene clusters involved in notoamide biosynthesis. The genomes of A. amoenus 
and A. protuberus were sequenced and annotated for candidate genes involved in the formation 
of secondary metabolites, marking the first biosynthetic gene cluster for the class of 
bicyclo[2.2.2]diazaoctane fungal alkaloids (Table 1-1).
47
 Two putative prenyltransferases, NotC 
and NotF, were identified from the biosynthetic gene cluster and expressed for biochemical 
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Scheme 1-1. Notoamide biosynthetic pathway. Biochemically confirmed and characterized gene products are 
colored in red. 
 
 
characterization. In this study, NotF was determined to be a reverse prenyltransferase responsible 
for the formation of deoxybrevianamide E. NotC, on the other hand, was determined to be a 
normal prenyltransferase and the notoamide S synthase.  
These data collected by biomimetic syntheses, isotope labeling incorporation studies, and 
bioinformatic and biochemical investigations together formed the foundation of our 
understanding of notoamide biosynthesis. Through further comparative analysis with other 
sequenced genomes from the bicyclo[2.2.2]diazaoctane family of producing organisms, we were 
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able to generate a putative biosynthetic pathway resulting in the formation of notoamide A 
(Scheme 1-1).
48
 Briefly, the formation begins with the nonribosomal peptide synthetase (NRPS) 
NotE, which fuses proline to tryptophan and offloads the common indole alkaloid precursor, 
brevianamide F, via a condensation domain. Brevianamide F is then prenylated by NotF to yield 
deoxybrevianamide E, which is then hydroxylated by NotG (unconfirmed) to yield 6-OH-
deoxybrevianamide E. Notoamide S is synthesized by NotC and represents a branching point for 
notoamide biosynthesis. If the molecule does not undergo IMDA construction to form the 
bicyclo[2.2.2]diazaoctane ring, it will instead undergo a pyran ring closure to give notoamide E. 
Notoamide E will then undergo an epoxidation and pinacol rearrangement facilitated by NotB to 
form notoamides C and D. If, at the branch point, notoamide S instead undergoes the IMDA 
reaction, notoamide T will be formed instead. It is at this biosynthetic step that the enantio-
divergence is observed. Notoamide T then undergoes a pyran ring closure to form stephacidin A, 
which then proceeds through a pinacol rearrangement reaction via NotI to yield notoamide B. 
Notoamide B is finally hydroxylated to yield notoamide A. 
 The biosynthetic pathway of notoamide presents a number of particularly rare and 
intriguing biosynthetic reactions. The first is the unusually constructed NRPS, which does not 
follow the typical C-A-T domain organization of these megasynthases.
49
 The second are the 
semipinacol rearrangement reactions that generate the spirooxindole moiety of these molecules. 
This is a reaction infrequently observed in natural products and even less understood from a 
biochemical perspective.
50
 Finally, the answer to whether an IMDA enzyme exists in nature 
remains elusive to the biosynthetic community. Although biomimetic syntheses have 
demonstrated the logic of constructing the bicyclo[2.2.2]diazaoctane core via IMDA reaction, 
there has been little to no evidence of an enzyme that can catalyze an IMDA reaction. 
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1.4 The Malbrancheamides 
 
Malbrancheamide was originally discovered from Malbranchea aurantiaca, a fungus isolated 
from bat guano by the Mata laboratory.
17
 The compound was soon discovered to inhibit 
calmodulin (CaM) in a concentration-dependent manner, indicating its potential therapeutic use 
in a variety of ion channel regulatory functions including anti-tumoral, smooth muscle relaxants, 
and anti-psychotic effects.
51
 CaM is a widely used Ca
2+
-binding protein involved in the 
regulation of many Ca
2+
-dependent cellular activities, including but not limited to 
neurodegenerative disease, cancer, and inflammatory disease.
52
 Premalbrancheamide was shown 
to act as a functional inhibitor of phosphodiesterase 1 (PDE1), while the halogenated forms 
function as classical inhibitors that bind the CaM-Ca
2+
 complex, with the dichlorinated species 
showing the strongest affinity.
53
 Currently, the malbrancheamides are the only members of the 
bicyclo[2.2.2]diazaoctanes to exhibit these clinical effects. 
 In comparison to its fellow bicyclo[2.2.2]diazaoctane compounds, malbrancheamide is 
currently the only identified molecule to contain halogen atoms in its structure. Halogenated 
molecules have demonstrated use in medicinal chemistry. Presence of halogens has been shown 
to be critical for the biological activity of many compounds, including vancomycin and 
chloramphenicol, and are a rapidly expanding category with over 3800 identified organohalogen 
compounds discovered by 2003.
54,55
 Nevertheless, halogenase mechanisms and their flexibility in 
substrate acceptance are still underexplored.
56–58
 Recent investigations have provided evidence 
supporting theories about the regioselective halogenation mechanisms, and attempts to 
reengineer the binding pocket to accept nonnative substrates for chemical transformation have 
been shown to be successful.
59–61
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Figure 1-4. Comparison of biosynthetic gene clusters from A. protuberus (not), A. amoenus (not’), P. fellutanum 
(phq), and M. aurantiaca (mal). Genes identified with comparable function are depicted in the same color across 
gene clusters. 
 
 Similar to the notoamides, malbrancheamide has also been investigated through 
biomimetic syntheses and isotopically enriched precursor incorporation studies. 
Premalbrancheamide was synthesized and delivered to M. aurantiaca to demonstrate the 
formation of malbrancheamide B.
62
 Interestingly, no formation of isotopically labeled 
malbrancheamide was observed from this study. Synthetic schemes have also been applied to the 
formation of malbrancheamide and malbrancheamide B,
25
 which demonstrated the variety of 
isomers that could be formed by the IMDA reaction by synthetic means. Efforts to overcome this 
challenge and produce an enantioselective product were developed to yield a domino reaction 
sequence with good diastereofacial control,
63
 and eventually approaches were developed to yield 
malbrancheamide B and its enantiomer, ent-malbrancheamide B.
64,65
 
 The biochemical approach to elucidating the biosynthetic mechanisms involved in the 
formation of malbrancheamide was initiated in the Sherman laboratory in collaboration with the 
Williams group. Because we already had the added benefit of previously identifying the 
notoamide gene cluster, this time we could begin with a comparative analysis of putative 
biosynthetic gene clusters across the malbrancheamide, paraherquamide, and notoamide species 
(Figure 1-4).
48
 The analysis facilitated the determination of homologous gene products based on 
amino acid sequence analysis. Homologous gene products were then assumed to perform the 
same or similar function within their respective biosynthetic systems. Based on these data, we 
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Scheme 1-2. Proposed malbrancheamide biosynthetic pathway. Gene products that have been biochemically 
characterized are colored in red. 
 
 
were able to construct a putative biosynthetic scheme for the formation of malbrancheamide 
(Scheme 1-2). Briefly, proline and tryptophan are fused by the MalG NRPS, which offloads the 
product by a reductase domain to yield the aldehyde of the dipeptide. The reactive aldehyde 
group then facilitates the spontaneous cyclization to yield the azadiene, which is then reverse 
prenylated by MalB or MalE prenyltransferases to introduce the dienophile that can undergo 
IMDA construction to form premalbrancheamide. Premalbrancheamide is then chlorinated once 
to form malbrancheamide B and a second time to form malbrancheamide. 
 The malbrancheamide biosynthetic system also presents its own unique chemistry in a 
predicted total of three key steps. Firstly, the NRPS ends in a rare terminal reductase domain that 
is predicted to facilitate formation of the monooxopiperazine versus the dioxopiperazine core 
that would otherwise yield the common intermediate brevianamide F seen in the notoamide 
biosynthetic pathway (Scheme 1-1). Secondly, the biosynthesis of malbrancheamide is also 
proposed to undergo an IMDA reaction to form the bicyclo core. Lastly, premalbrancheamide 
would be halogenated to form malbrancheamide. The identification of only one halogenase 
initially suggested that it may be responsible for a sequential or simultaneous dichlorination, and 
thus presented an interesting question of how the substrate is accommodated within the active 
site of the protein for the halogenation reaction. 
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Figure 1-5. The basic components of a Diels-Alder reaction. 
 
1.5 The intramolecular Diels-Alder hypothesis 
 
The Diels-Alder reaction was developed in 1920 by Prof. Otto Diels and his student Kurt 
Alder.
66
 It is an extremely versatile, commonly used reaction today in synthetic chemistry and 
earned Diels and Alder a Nobel Prize in 1950. The pericyclic [4+2] cycloaddition reaction has 
been studied thoroughly to understand the formation of endo- versus exo- products, and in the 
1950s began to be applied to the total synthesis of natural products.
67
 The numerous synthetic 
investigations performed suggested that nature was also capable of devising a strategy for 
performing the Diels-Alder reaction, and that the approach was likely involved in these natural 
product pathways. Additionally, the necessity of a Diels-Alder biocatalyst was supported by the 
presence of preceeding intermediates, the necessity of a catalyzing action to generate the product, 
and the chirality of the resulting molecules.
68
 
 Natural products formed by a presumed Diels-Alder mechanism occur frequently in 
nature, with well over 150 examples to date.
68
 However, few biomolecules have been 
demonstrated to be involved with the reaction biosynthetically, and many have been met with 
justifiably skeptical debate. Of the more successful investigations include the use of antibodies.
69
 
Other investigations involved the use of RNA as ribozymes, which perform a reaction similar to 
the Lewis acid catalysis of the Diels-Alder reaction.
70,71
 Natural protein catalysts, on the other 
hand, have remained a more elusive subject of interest. Two proteins have been purified to 
homogeneity and shown to generate the Diels-Alder product from the substrate.
72
 However, the 
mechanism by which this occurs is still an intense topic of debate. The first of the two examples 
  
14 
 
is LovB, a type I iterative PKS, that is involved in the synthesis of lovastatin, a cholesterol-
lowering agent.
73
 In reactions containing LovB and LovC incubated with the predicted 
hexaketide intermediate, the pericyclic reaction product was observed. However, the large 
molecular weight of LovB (335 kDa) is an inherent hurdle barring progress in further 
biochemical studies of the protein. The second of the two examples is the macrophomate 
synthase (MPS) enzyme.
74
 Originally, the findings supported the identity of MPS as a potential 
Diels-Alderase.
75,76
 However, through quantum and molecular mechanics simulations,
77
 
combined with the solution to the crystal structure and further enzymology studies on the 
enzyme,
78,79
 evidence was found contradicting the Diels-Alder mechanism, instead supporting 
the formation of macrophomate by a Michael-aldol mechanism. More recently, during the 
investigation of spinosyn A biosynthesis, SpnF was determined to be a cyclase that catalyzes the 
[4+2] cycloaddition reaction.
80
 While cyclization can occur nonenzymatically, the addition of 
SpnF was shown to increase the yield of product quantitatively. Furthermore, computational 
studies have supported the theory that SpnF serves as a scaffold or chaperone-like protein for the 
IMDA reaction, and that the enzyme additionally stabilizes the transition structure and thus 
reduces the activation energy of the reaction.
81
 
 Indeed, the existence of an enzymatic Diels-Alderase has long been sought after and is 
one of the main driving forces behind our investigation of the fungal indole alkaloid biosynthetic 
pathways. As described in sections 1.3 and 1.4, we expect that the formation of the 
bicyclo[2.2.2]diazaoctane core arises by an IMDA reaction. Due to the general lack of 
understanding of the biochemistry that drives this reaction, we believed that identifying the 
Diels-Alderase from any of these biosynthetic pathways would be a highly impactful 
contribution to the field. Similar to what has been previously proposed, we believed that our 
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Diels-Alderase would perform a dual-function, i.e., it would catalyze its biosynthetic reaction 
and simultaneously act as a scaffold for the IMDA reaction to occur. It was with this hypothesis 
in mind that we began our biochemical investigation of the biosynthetic pathways of the 
malbrancheamides, notoamides, and paraherquamides.  
1.6 Dissertation directions and goals 
 
For my own dissertation work described herein, I focused primarily on the elucidation of key 
chemical transformation steps from the malbrancheamide and notoamide biosynthetic pathways. 
I began by investigating our primary targets that we believed would be responsible for the IMDA 
reaction and investigated the putative identity of each gene product in the two gene clusters to 
identify the putative Diels-Alderase. The prenyltransferase in the malbrancheamide biosynthetic 
pathways was the primary target of interest. A second candidate would be the enzyme involved 
in the following step: the halogenase. The third primary candidate would be the NRPS 
megasynthase, in case the prenylation event occurs as an earlier event and our order for 
biosynthesis is incorrect. In the notoamide biosynthetic pathway, we believed that one of the 
oxidoreductases would be involved in the oxidation event preceeding the IMDA reaction. NotB 
and NotI have been ruled out as candidates for this reaction by my colleague, Shengying Li, and 
myself, respectively.  
 I never identified the enzyme responsible for catalyzing the IMDA event. However, 
under the assumption that all biosynthetic genes are included within the gene clusters that we 
have mined, one of the gene products must be responsible for the Diels-Alder reaction. By 
process of elimination, the Diels-Alderase will be found eventually. However, the general lack of 
evidence and biochemical information available for Diels-Alderases makes the identification of 
the Diels-Alderase a very challenging investigation, as discussed in section 1.5. I am confident 
  
16 
 
that the Diels-Alderase will eventually be found, and that our understanding of the 
bicyclo[2.2.2]diazaoctane biosynthetic pathways will eventually lead us to the correct candidate. 
For my dissertation, I have contributed towards this goal by enhancing our understanding of the 
various rare and interesting biosynthetic transformations involved in the formation of these 
intriguing molecules. Rather than identifying the still elusive Diels-Alderase, my dissertation 
work therefore instead focuses on the identification and characterization of three key steps in 
fungal indole alkaloid biosynthesis, making a significant contribution overall to our 
understanding of these biosynthetic pathways. 
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Chapter 2 
2 Formation of the spirooxindole moiety 
 
2.1 Introduction 
 
A semipinacol rearrangement is predicted to generate the spirooxindole moiety found in the 
Notoamides, Paraherquamides, and Spiromalbramide (Figure 2-1).
82,83
 Pinacol rearrangements 
have been proposed to occur in the biosynthetic pathways of various natural products, including 
 
Figure 2-1. Representative fungal prenylated indole alkaloids 
bearing the spirooxindole moiety. 
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the Aurachins, 2-Tropolone, Brevianamides, and Spiromalbramide, among others.
84–86
 
Filamentous fungi, in particular, have been found to produce a number of spirocyclic compounds, 
including Geodin, Griseofulvin, Austinol, and Fumitremorgin.
50,87–90
 However, there has been 
little biochemical evidence to support the direct role of specific enzymes in the rearrangement 
reaction, leaving an incomplete understanding of the formation of these moieties in secondary 
metabolism.
91
 
The Notoamides are a relatively new class of metabolites in the indole alkaloid 
 
Scheme 2-1. Putative biosynthetic pathway of the Stephacidin and Notoamides. Gene products that have been 
biochemically characterized are labeled in red. 
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family.
40,92
 A fascinating finding regarding these fungal natural products is that (-)-Stephacidin A, 
(+)-Notoamide B, and (+)-Notoamide A are produced by the terrestrial strain Aspergillus 
amoenus (formerly Aspergillus versicolor NRRL 35600), while the enantiomeric products (+)-
Stephacidin A, (-)-Notoamide B, and (-)-Notoamide A are produced by the marine Aspergillus 
protuberus (formerly Aspergillus sp. MF297-2).
93
 The formation of enantiomeric natural 
products identified from one or more species is a highly unusual phenomenon that has been 
observed in less than 1% of the biosphere metabolome to date.
94
 The existence of distinct 
metabolic systems that create exact antipodes suggests that the strains have evolved one or more 
biosynthetic gene products (e.g. NotD, NotH, and NotI) that catalyze an identical enzymatic 
reaction to produce and further modify enantiomeric compounds.
22
 To this end, extensive 
biomimetic synthetic schemes have been devised to generate Stephacidin A and Notoamide B.
95
 
These studies have supported the hypothesis that one or more biosynthetic enzymes determine 
the chirality of the molecule, however, the molecular mechanisms that control this divergence 
have remained a mystery. Thus, we reasoned that analysis of the flavin oxidases likely involved 
in formation of the spirooxindole functionality would provide further insights into the basis of 
enantiomeric induction in these systems, and whether these enzymes catalyze enantioselective 
reactions. 
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Table 2-1. Comparison of amino acid sequences of Not and NotI´ 
Not proteins 
(AA) 
Not’ proteins 
(AA) 
Function (% AA identity) 
NotA (339) NotA’ (334) Negative regulator 70%  
NotB (456) NotB’ (455) FAD monooxygenase 88%  
NotC (427) NotC’ (426) Prenyltransferase 87%  
NotD (621) NotD’ (612) Oxidoreductase 80%  
NotE (2241) NotE’ (2225) NRPS [A-T-C-A-T-C] 79%  
NotF (453) NotF’ (435) Prenyltransferase 79%  
NotG (544) NotG’ (544) P450 monooxygenase 87%  
NotH (502) NotH’ (499) P450 monooxygenase 84%  
NotI (434) NotI’ (433) FAD monooxygenase 85%  
NotJ (371) NotJ’ (362) Unknown 80%  
 
 The genomes of A. protuberus and A. amoenus have previously been sequenced in our 
laboratories.
96
 The gene clusters were identified through in silico database mining, followed by 
open reading frame (orf) and BLAST analysis to complete a deeper annotation of the metabolic 
systems. These data, combined with previous isotopically enriched precursor incorporation 
studies supported our proposed biosynthetic pathway for the Notamides.
22
 Comparison of the 
two gene clusters shows an overall 71% DNA sequence identity (between notA-J), indicating a 
closely related ancestry between the two gene clusters and a high similarity between sequences 
of putative gene products (Table 2-1).
97
 However, bioinformatic analysis provided a limited 
understanding of the biosynthetic pathway and little mechanistic information about the sequence 
divergence observed between the two enantiomeric natural products. Consequently, we were 
motivated to investigate the biochemical transformations involved in the formation of the 
Notoamides, and determine the basis for the structural branch-point that generates the antipodal 
indole alkaloid molecules. 
Recently, significant progress has been made to elucidate the biosynthetic genes involved 
in the creation of the Notoamides (Scheme 2-1). NotF and NotC have previously been 
characterized as reverse and normal prenyltransferases, respectively, while NotB has been 
characterized as an FAD-dependent oxidase.
82,96
 Herein, we report the biochemical function of 
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NotI from A. protuberus as a flavin-dependent monooxygenase (FMO) that catalyzes a 
semipinacol rearrangement to generate the spirooxindole moiety found in many of the 
bicyclo[2.2.2] diazaoctane fungal indole alkaloids. We also report the biochemical activity of 
NotI´ and PhqK as the first heterologously expressed and biochemically characterized gene 
products from A. amoenus and P. fellutanum, respectfully. Finally, we have demonstrated the 
ability to diversify the pool of Notoamide compounds by characterizing Notoamide T9 as a new 
metabolite generated through the remarkable substrate flexibility of homologues NotI, NotI´, and 
PhqK.  
2.2 Results 
2.2.1 Determination of NotI and NotI´ as the (+)-Notoamide B synthase via semipinacol 
rearrangement. 
 
The functions of NotI and NotI´, predicted FAD-dependent monooxygenases, were investigated. 
Compounds (+)-16, (-)-16, and (±)-16 were separately incubated with NotI or NotI´ at 28°C for 
approximately 16 hours (Figure 2-2A). Samples were extracted three times with CHCl3 and 
subjected to analysis using LC-MS compared directly with synthetic standards (Figure 2-2B). 
The product 17 (448.2252 m/z) was observed by LC-MS Q-TOF for all reactions.  
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Figure 2-2. (A) Native reaction for NotI and NotI´ based on catalytic 
activity against (+) and (-)-16. (B) HPLC analysis depicting extracted ion 
chromatograms (EICs) of (a) authentic (+)-17; (b) NotI´ + (-)-16; (c) 
NotI + (-)-16; (d) authentic (-)-16. 
The reactions of NotI with Stephacidin A to generate Notoamide B were fit to Michaelis-
Menten kinetics (Figure 2-8). The Km and Vmax values for NotI using (-)-16 as substrate were 
determined to be 39 + 11 µM and 49 + 3 µM/min, respectively. The kcat was determined to be 20 
min
-1
, and the apparent specificity constant (kcat/Km) of the enzymatic reaction was shown to be 
0.50 µM
-1
 min
-1
.  
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Table 2-2. Structures of substrates tested and summary of products formed in reactions with NotI, NotI′, and PhqK 
2.2.2 Analysis of NotI Substrate Flexibility. 
Next, we sought to determine the exact timing of epoxidation and pinacol rearrangement in 
Notoamide biosynthesis. Reactions were similarly conducted using NotI and NotI´ with 
compounds 6,
98
 7,
98
 8,
99
 9,
44
 10,
40
 (±)-15,
46
 (±)-16,
100
 (±)-6-epi-stephacidin A (18),
93
 and 
analyzed by LC-MS Q-TOF. To our surprise, both enzymes demonstrated a remarkable range of 
substrate tolerance, leading to new products with masses of [M+16]. With compounds 9 and 10, 
the reactions were able to generate more than one visible product (Table 2-2). 
The monooxopiperazines from the Malbrancheamide and Paraherquamide pathways were 
also tested in vitro with NotI and NotI´ (Figure 2-9), but these reactions failed to convert 
substrates into products. Additionally, reactions with compound 6 did not generate observable 
products, suggesting that [C-2] prenylation of the indole could be important for substrate 
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recognition.  
2.2.3 Determination of PhqK activity and substrate flexibility. 
 
We also examined the substrate flexibility of PhqK, the NotI homologue in the Paraherquamide 
biosynthetic gene cluster from P. fellutanum.
97
 The enzyme was tested in reactions with 
monooxo- and dioxopiperazine substrates and analyzed by LC-MS Q-TOF (Table 2-2, Table 
2-3). As expected, PhqK was able to convert its presumed native substrate Preparaherquamide 
(23)
101
 as well as the monooxopiperazine substrates 20,
25
 21,
25
 and 22
53
 from the 
Malbrancheamide pathway. Additionally, PhqK was able to catalyze the formation of new 
products with [M+16] masses with 8, 9, 15, and 16.  By contrast, no oxidative reactions were 
observed with 18.  
2.2.4 Determining the structure of Notoamide T9. 
Table 2-3. Structures of monooxopiperazine substrates tested and summary of 
products formed in reactions with PhqK. 
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Figure 2-3. (A) Observed conversion from Notoamide T to Notoamide T9 by NotI. (B) 
HPLC analysis of NotI in vitro reaction with Notoamide T (15) to generate new 
compound Notoamide T9 (19): (a) 15 + NotI´; (b) 15 + NotI; (c) 15 in reaction solution 
without enzyme. The asterisk denotes a possible diastereomer of Notoamide T (15). (C) 
Planar structure of Notoamide T9 (19) showing COSY correlation with bold bonds and 
HMBC correlations with arrows. 
 
Assuming NotI and NotI´ would perform a similar reaction on Notoamide T, we predicted that a 
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new metabolite may have been formed and investigated the structure by NMR spectroscopy. The 
product was generated in large scale reactions containing NotI and (±)-Notoamide T. The desired 
product was then isolated and purified via HPLC to yield approximately 2 mg of purified 
compound. NMR analysis was performed to determine the structure of Notoamide T9 (Figure 
2-3).  
Notoamide T9 (19) was obtained as white amorphous solid and possesses a molecular 
formula of C26H31N3O4 as suggested by HRESIMS based on [M+H]
+
 ion peak at m/z 450.2414 
(Figure 2-23), representing 13 degrees of unsaturation. Moreover, the UV spectrum in methanol 
with λmax at 242, 309, and 335 (sh) nm was indicative of aromatic functionality. The 
1
H (Figure 
2-26) and 
13
C NMR (Figure 2-27) data, recorded in DMSO-d6, indicated the presence of amides 
or lactams with at least three carbonyl carbons with chemical shifts at δ 169.5, 173.1, and 183.1 
(Table 2-2). In addition, HSQCAD spectra (Figure 2-28) revealed the presence of four methyl 
groups, six methylenes and three methine carbons (Table 2-4). Further, analysis showed eight 
13C NMR signals between δ 107.5 and 155.3 (Table 2-4) indicating the presence of four double 
bonds, which in addition to the above mentioned groups, cumulatively accounts for only seven 
degrees of unsaturation. Hence, there must be at least six rings in the structure, and therefore 
extensive 2D NMR experiments (HMBC and COSY) were employed (Figure 2-29, Figure 2-30), 
leading to the establishment of the connectivity of deduced functional groups to elucidate the 
planar molecular structure 19 (Figure 2-3). 
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Table 2-4. NMR spectroscopic data for Notoamide T9 (19) in DMSO-d6 at 700 MHz. 
  δC δH, multi (J in Hz) COSY HMBC 
1 43.1 3.38, m 2 2, 3, 4 
2 29.1 1.91, dd (1.93, 
1.92) 
1, 3 1, 3, 4 
  1.78 (m) 1  
3 24.2 1.99 (m) 1, 3 1, 2, 4 
  1.73 (m)   
4 67.9    
5 28.6 2.51 (m) 6 4, 6 
  1.23 (m)   
6 55.3 3.24, t (3.2) 5 18, 19, 28 
7 44.7    
8 61.2    
9 120.3    
10 123.4 6.82, d (6.8) 11 9, 12 
11 107.5 6.41, d (6.8) 10 9, 13 
12 155.3    
13 109.8    
14 141.1    
15 NH 9.07   
16 183.1    
17 33.2 2.77, d (2.7)  6, 7, 9, 19 
  2.13, d (2.7)  7, 9, 19 
18 65.2    
19 169.5    
20 N    
21 173.2    
22 NH 8.51   
23 23.2 3.18, m 24 12, 13, 14 
24 122.5 5.13, t (5.1) 23  
25 130.3    
26 25.3 1.61, s  25, 27 
27 17.6 1.69, s  25, 26 
28 22.9 0.68, s  6, 7, 29 
29 19.3 0.69, s  8, 28 
  
2.3 Discussion 
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Pinacol rearrangements have long been predicted as steps in the biosynthetic schemes of 
numerous natural products, but few examples have been characterized. Gene disruption studies 
performed on the GsfF P450 monooxygenase support its role in a comparable reaction in the 
Griseofulvin biosynthetic pathway.
102
 Dihydrogeodin oxidase is a rare blue copper protein that 
generates diradicals involved in formation of the spiro center in Geodin.
103
 FqzB, a FMO from 
the Fumitremorgin gene cluster, catalyzes the spirocycle rearrangement in Spirotryprostatin 
synthesis.
104
 Interestingly, this enzyme was found to be specific for compounds containing a p-
methoxy group and presents an intriguing contrast to the FMOs in this study that exhibit a wide 
degree of substrate flexibility. In comparison, we believe that we have identified three 
particularly unusual cases of FMO enzymes (NotI, NotI´, PhqK) that could be further engineered 
for use in chemoenzymatic synthetic approaches due to their inherent substrate flexibility.  
We initially hypothesized that the NotI, NotI´, and PhqK proteins would be specific for 
their respective enantiomers, as enzymes are typically expected to be substrate and face selective 
in their reactions with some exceptions. However, our experimental findings have revealed the 
high degree of flexibility that these FMOs exhibit, with no apparent enantioselective 
discrimination. In contradistinction, the facial selectivity of the FMO-catalyzed oxidation 
appears highly diastereoselective, delivering the oxygen atom from the least-hindered face of the 
2,3-disubstituted indole substrate species, and is thus a “substrate-controlled” reaction. These 
findings support our proposed biosynthetic pathway, in which NotI and NotI´ are not responsible 
for the enantio-divergence in compounds produced between the two Aspergillus species, and that 
the creation of antipodal Notoamides is instead due to an earlier step in the biosynthetic 
pathway.
100,105,106
 With our current knowledge of the biochemical transformations involved, we 
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suspect that NotD or NotH, the gene product currently suspected of being responsible for the 
intramolecular Diels-Alder reaction, is the likely candidate for the enantio-divergent step. 
NotI and NotI´ demonstrated an unusual amount of substrate tolerance, converting many 
intermediates from the pathway to various products. Based on these data, it is highly possible 
that NotI/NotI’ also perform as the Brevianamide E synthase, the Notoamide J synthase, and 
Versicolamide B synthase in their respective pathways, although further investigation is required 
to confirm these assignments.
39,93,107
 The acceptance of many substrates suggests that there may 
be some functional redundancy in the biosynthetic pathways of the Notoamide-producing 
systems. The other Notoamide FMO gene product NotB shares 42% protein sequence identity 
and 59% similarity with NotI.
82
 However, the fact that they can catalyze the same reactions on 
substrate Notoamide E was unexpected. We propose that within this system, NotB acts as a 
specialized, more efficient enzyme dedicated to the conversion of Notoamide E, while NotI 
behaves as a more universal catalyst at a lower rate of efficiency. 
We also investigated the role of PhqK in the Paraherquamide pathway, one that involves 
the formation of a monooxopiperazine as opposed to the dioxopiperazines observed in the 
Notoamides and Stephacidins. PhqK and NotI share 34% amino acid sequence identity, thus 
suggesting that they perform comparable roles in their respective biosynthetic pathways. We 
sought to determine whether PhqK would be selective towards monooxopiperazine compounds, 
as NotI exhibited a specificity for dioxopiperazine metabolites. Investigating the activity of 
PhqK in vitro revealed that both monooxo- and dioxopiperazines can serve as PhqK substrates 
(Figure S5, Table 2-2), again demonstrating the broad, yet differential specificity in these 
biosynthetic FMOs.  
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Additionally, we were able to generate a novel indole alkaloid metabolite, Notoamide T9, 
further expanding the chemical diversity of bicyclo[2.2.2]diazaoctanes using in vitro reactions. 
The existence of Notoamide T9 suggests that there may be more than one pathway to the 
formation of Notoamide B. However, isotopically enriched precursor incorporation studies with 
Stephacidin A suggest that the proposed order depicted in Scheme 1 is likely to be the preferred 
route.
45
 
In this investigation, three examples of flavin-dependent monooxygenases responsible for 
the formation of the spirooxindole center of various bicyclo[2.2.2]diazaoctane fungal alkaloids 
via semipinacol rearrangement were characterized. Although the exact mechanism of this 
reaction remains unknown, we believe the C2=C3 bond of the indole is epoxidized by the FMO 
on the less-hindered face, as has been observed in synthetic approaches.
100
 The reactive epoxide 
 
Figure 2-4. Proposed biosynthetic conversion of (±)-16 to (±)-17. 
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intermediate then collapses to form the 2-alkoxyindole iminium intermediate, followed 
immediately by a [1,5] sigmatropic shift to provide (+)-17 (Figure 2-4). These findings suggest 
that an unusual substrate-controlled semipinacol rearrangement reaction is involved in 
Notoamide and Paraherquamide biosynthesis. Additionally, we have reported the first 
biochemical investigation of biosynthetic enzymes from the A. amoenus and P. fellutanum gene 
clusters. These data have important implications for the inherently flexible and previously 
underexplored FAD-dependent monooxygenases in fungal alkaloid biosynthesis, as well as for 
their origins in evolutionary biology. Further studies are being performed to enhance our 
understanding of the mechanisms that drive these unusual and intriguing reactions. 
2.4 Materials and Methods 
 
1. Fungal strains and Culture Conditions 
Aspergillus amoenus, Aspergillus protuberus, and Penicillium fellutanum ATCC 20841 spores 
were generated on YPD agar plates over the course of 7 days. Spores were harvested into 5 mL 
sterile water per plate by gently scraping the surface of the culture with a sterile inoculating loop. 
Spores were stored at -80°C until ready to use. Genomic DNA was harvested using Wizard 
Genomic DNA Purification Kit from Promega. 
 
2. cDNA preparation and cloning of notI, notI′, and phqK 
Total RNA was extracted from a filter paper dried 17
th
 day mycelia (roughly 500 mg fungal mat) 
culture of Aspergillus protuberus statically cultivated in liquid medium (50% seawater with 2.0% 
malt extract and 0.5% peptone) at 28°C, using Invitrogen PureLink RNA Mini Kit by following 
the plant tissue processing protocol. RNA was treated using DNase I. cDNA was generated using 
Invitrogen Superscript First Strand Synthesis. PCR was used to amplify NotI from the cDNA 
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template. Additionally, a codon optimized construct was purchased from GeneArt, Life 
Technologies and used in all enzymology studies. To generate notI′, introns were predicted by 
analysis using Softberry Fgenesh-M. Further analysis was performed by comparison with the 
notI sequence, which has 81% DNA sequence identity. The notI′ and phqK genes were amplified 
from genomic DNA using overlapping PCR using primers in Table S1.  Amplified genes were 
cloned into pET28b vectors using restriction enzyme digest and ligation. Plasmids were 
transformed into E. coli DH5α for screening and plasmid maintenance. 
 
3. Overexpression and Purification of Protein for Enzymology  
The Escherichia coli BL21 (DE3) transformant containing PMCSG7-notI and Takara chaperone 
pGKJE8 was grown at 37°C overnight in LB media containing 50 µg/mL of ampicillin and 25 
µg/mL of chloramphenicol. 25 mL of culture was used to inoculate 1 L of TB media containing 
the aforementioned concentrations of antibiotic and 4% glycerol, and cultures were 
supplemented with 0.5 mg/mL L-arabinose and 5 ng/mL tetracycline to induce chaperone 
expression. Cells were grown at 37°C for roughly 4 hours until A600 reached 0.6-1.0, and 
isopropyl β-D-thiogalactoside (IPTG, 0.2 mM) along with riboflavin (50 µM) was added to 
induce protein overexpression overnight at 18°C. The Escherichia coli BL21 pRARE 
transformant containing pET28b-notI′ and Takara chaperone pTf16 was grown at 37°C overnight 
in LB media containing 50 µg/mL of kanamycin, 25 µg/mL of chloramphenicol, and 100 µg/mL 
of spectinomycin. 25 mL of culture was used to inoculate 1 L of TB media containing the 
aforementioned concentrations of antibiotic and 4% glycerol, and cultures were supplemented 
with 0.5 mg/mL L-arabinose to induce chaperone expression. Cells were grown at 37°C for 
roughly 4 hours until A600 reached 0.6-1.0, and isopropyl β-D-thiogalactoside (IPTG, 0.2 mM) 
  
33 
 
along with riboflavin (50 µM) was added to induce protein overexpression overnight at 15°C. An 
E. coli BL21 pRARE transformant containing pET28b-phqK grown at 37°C overnight in LB 
media containing 50 µg/mL of kanamycin was used to inoculate 6 L LB supplemented with 
kanamycin. The cells were grown at 37°C to A600 ~ 0.8 and subsequently cooled to 18°C and 
grown overnight (12-16 h) after the addition of isopropyl β-D-thiogalactoside (IPTG, 1 mM) and 
riboflavin (50 µM). 
All purification steps were conducted at 4°C. Briefly, 2 L of expression culture were spun 
down at 5,500 xg to yield approximately 20 mL of cell pellet volume. Harvested cell pellets were 
resuspended in 60 ml of lysis buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% 
v/v glycerol, pH 8) and lysed by sonication. Insoluble material was removed by centrifugation at 
38,000 xg for 30 min, and the supernatant was batch-bound for 1 hour to 4 mL of Ni
2+
-NTA 
slurry (Novagen) that was equilibrated in lysis buffer. This batch-binding mixture was poured 
through a 50 ml fritted glass column where the retained resin was washed with 100 mL of lysis 
buffer, 50 mL of wash buffer (20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% v/v 
glycerol, pH 8), and finally 10 ml of elution buffer (250 mM imidazole, 50 mM NaH2PO4, 300 
mM NaCl, 10% v/v glycerol, pH 8). Protein in the eluate was exchanged into storage buffer (50 
mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 7.3) using PD-10 columns. 
Samples were then flash frozen with liquid N2 and stored at -80°C. PhqK was purified using 
similar methods with the exception of storage buffer, which was composed of 10 mM HEPES 
pH 7.6, 50 mM NaCl, 0.1 mM EDTA, 0.2 mM TCEP. 
 
4. Enzyme assays and LC-MS Q-TOF analysis 
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The standard enzyme assay containing 0.5 mM substrate, 2.5 mM NADH, and 20 µM enzyme in 
100 µL reaction buffer  (50 mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 
7.3) was performed at 28°C overnight. Each reaction was extracted 3 times with 200 µL 
chloroform, and the extract was dried down under N2 gas. The product was resuspended in 100 
µL methanol for LC-MS Q-TOF analysis. HPLC conditions for NotI/NotI reactions: ZORBAX 
Eclipse Plus C18 reverse phase column, 3.5 µm, 4.6 x 150 mm; monitoring wavelengths 240 nm 
and 280 nm; scanning 200 to 1200 m/z; solvent A: water + 0.1% formic acid, solvent B: 95% 
acetonitrile in water + 0.1% formic acid; flow rate: 0.8 mL/min; mobile phase: 20% B over 2 
min, 20-100% B over 10 min, 100% B over 5 min, 100-20% B over 1 min, 20% B over 5 min. 
HPLC conditions for PhqK reactions: Agilent Extend C18 reverse phase column. 5 µm, 4.6 x 
150 mm; monitoring wavelengths 240 nm and 280 nm; scanning 200 to 2000 m/z; solvent A: 
water + 0.1% formic acid, solvent B: 95% acetonitrile in water + 0.1% formic acid; flow rate: 0.4 
mL/min; mobile phase: 5% B over 1 min, 5-100% B over 20 min, 100% B over 5 min, 100-5% B 
over 1 min, 5% B over 5 min 
5. NotI kinetic assays and LC-MS Q-TOF analysis 
250-µL reactions contained 2.5 µM NotI, 5 mM NADH, and 0.1 mM FAD in reaction buffer (50 
mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 7.3). Concentrations of 10, 20, 
40, 100, 150, 200, 300, and 500 µM (-)-16 were tested. The reactions were pre-warmed at room 
temperature for 5 minutes and initiated with addition of 5 mM NADH and mixed briefly. The 
reactions were stopped by transferring 50 µL reaction mixture to equal volume methanol, 
vortexing vigorously, and placing on ice. The samples were then centrifuged at 17,000 xg at 4°C 
for 25 minutes to pellet protein, and the supernatant was transferred to analysis vials for LC-MS 
Q-TOF analysis. HPLC conditions: ZORBAX Eclipse Plus C18 reverse phase column, 3.5 µm, 
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4.6 x 150 mm; monitoring wavelengths 240 nm and 280 nm; scanning 200 to 1200 m/z; solvent 
A: water + 0.1% formic acid, solvent B: 95% acetonitrile in water + 0.1% formic acid; flow rate: 
0.8 mL/min; mobile phase: 50% B over 2 min, 50-55% B over 5 min, 55-50% B over 30 sec, 50% 
B over 2.5 min. All experiments were performed in duplicate. Quantitative analysis was 
performed by extracting ions corresponding to substrate and product masses and calculating the 
area under each peak. The data were fit to the Michaelis-Menten equation.  
Name Sequence (5' -> 3') Function 
notI-F GGAGTTCCATATGGCTATAGACGGATCT notI amplification 
notI-F CAATGAAGCTTTCAACCAACCGGTATACC notI amplification 
FNdeI 
GGAATTCCATATG 
GCTATAGACGCATCTGGTGCTG notI ′ amplificaton 
RNotI 
ATAAGAATGCGGCCGC 
TTAATCCACCGGTATACCACCGAAG notI ′ amplificaton 
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Table 2-5. Primers for NotI, NotI′, and PhqK intron removal and amplification 
 
  
  
NotI′_Int1_F 
CAAGAGCTACCGTTTGGG 
AGACTTGATCAATGTGACCGGG notI ′ intron removal 
NotI′_Int1_R 
CCCGGTCACATTGATCAAGTCTCCCAAACG
GTAGCTCTTG notI ′ intron removal 
NotI′_Int2_F 
CGAGTGACAGAGAAGCTAAGGTACCAAAG
GGTTGCTGCAA notI ′ intron removal 
NotI′_Int2_R 
TTGCAGCAACCCTTTGGTACCTTAGCTTCT
CTGTCACTCG notI ′ intron removal 
PhqK_Int1_F ATGGGCTCTTTAGGTGAAGAAGTTCAAG phqK intron removal 
PhqK_Int1_R 
GTTGCTTTGAAGACCAATACAGTCTCCGAT
GGACTTCAGTATATTGCTTTTC phqK intron removal 
PhqK_Int2_F 
GAAAAGCAATATACTGAAGTCCATCGGAG
ACTGTATTGGTCTTCAAAGCAAC phqK intron removal 
PhqK_Int2_R 
CAGACGTCTAGGAGATTTCTTGTATCCTGA
TGAATGCAGAACCACGAAAAG phqK intron removal 
PhqK_Int3_F 
CTTTTCGTGGTTCTGCATTCATCAGGATAC
AAGAAATCTCCTAGACGTCTG phqK intron removal 
PhqK_Int3_R CTAGGGTGACTTGTTCTGCAATGG phqK intron removal 
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2.5 Appendix 
 
 
Figure 2-5. (A) 4-12% Bis-Tris in MES buffer SDS page analysis of NotI and NotI′. The calculated molecular 
weight of NotI is 47.1 kDa and the calculated molecular weight of NotI′ is 49.2 kDa. (B) 4-12% Bis-Tris in MOPS 
buffer SDS page analysis of phqK. The calculated molecular weight of PhqK is 51.2 kDa. 
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Figure 2-6. UV-Vis spectra of purified NotI protein solution (top) and the supernatant of denatured NotI protein 
solution (bottom). Denatured protein was generated by boiling for 15 minutes. The flavin cofactor peaks at 360 and 
450 nm are present in both the native protein solution and the denatured supernatant.  
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Figure 2-7. Identification of FAD as the non-covalently bound NotI flavin cofactor. (a) FMN standard; (b) FAD 
standard; (c) NotI supernatant after denaturation of protein by boiling and centrifugation. 
 
Figure 2-8. Kinetic curve of NotI against (-)-16. 
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Figure 2-9. Substrates used to test NotI, NotI′, and PhqK activities. 
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Figure 2-10. From EIC traces in Figure 2-2: (A) MS of (-)-16; (B) MS of (+)-17 formed from reaction with NotI; (C) 
MS of (+)-17 formed from reaction with NotI′. 
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Figure 2-11. LC-MS Q-TOF analysis depicting EICs of (a) NotI´ + (+)-16; (b) NotI + (+)-16; (c) A. protuberus 
isolated authentic (+)-16. Some (-)-17 is observed in the substrate trace (c). Integrating the traces to determine 
percent conversion yielded values of approximately 21% (-)-17 in trace (a), 15% (-)-17 in trace (b), and 14% (-)-17 
in trace (c). 
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Figure 2-12. Mass spectra of (A) (+)-16 standard; (B) (-)-17 produced by NotI; (C) (-)-17 produced by NotI′. 
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Figure 2-13. LC-MS Q-TOF analysis depicting EICs of (a) NotI´ + (±)-16; (b) NotI + (±)-16; (c) authentic (±)-16. 
The asterisk denotes a possible artifact from the reaction solution. 
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Figure 2-14. Mass spectra of (A) (±)-16 standard; (B) 17 produced by NotI; (C) 17 produced by NotI′. 
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Figure 2-15. LC-MS Q-TOF analysis depicting EICs of (a) NotI′ reaction with 7; (b) NotI reaction with 7; (c) 
authentic 7 standard. Product formed is denoted with P. 
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Figure 2-16. Mass spectra of (A) 7 standard; (B) Product formed from NotI + 7. 
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Figure 2-17. LC-MS Q-TOF analysis depicting EICs of (a) NotI′ reaction with 8; (b) NotI reaction with 8; (c) 
authentic 8 standard. Product formed is denoted with P. Asterisk denotes a possible diastereomer of 8. 
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Figure 2-18. Mass spectra of (A) 8 standard with 3 
13
C label; (B) Product formed from NotI + 8; (C) Product 
formed from NotI′ + 8. 
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Figure 2-19. LC-MS Q-TOF analysis depicting EICs of (a) NotI′ reaction with 9; (b) NotI reaction with 9; (c) 
authentic 9 standard. Product(s) formed is denoted with P. 
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Figure 2-20. Mass spectra of (A) 9 standard; (B) Product formed from NotI + 9 observed at 594.3 seconds; (C) 
Product formed from NotI + 9 observed at 540.0 seconds; (D) Product formed from NotI + 9 observed at 526.6 
seconds; (E) Product formed from NotI′ + 9 observed at 595.7 seconds; (F) Product formed from NotI′ + 9 observed 
at 538.5 seconds; (G) Product formed from NotI′ + 9 observed at 526.0 seconds. 
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Figure 2-21. LC-MS Q-TOF analysis depicting EICs of (a) NotI′ reaction with 10; (b) NotI reaction with 10; (c) 
authentic 10 standard. Product(s) formed is denoted with P. Asterisk denotes possible diastereomer of 10. 
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Figure 2-22. Mass spectra of (A) 10 standard with 2 
13
C label; (B) Product formed from NotI + 10 observed at 621.5 
seconds; (C) Product formed from NotI + 10 observed at 573.0 seconds; (D) Product formed from NotI′ + 10 
observed at 620.2 seconds; (E) Product formed from NotI′ + 10 observed at 573.1 seconds. 
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Figure 2-23. Mass spectra of (A) (±)-15 standard; (B) Product formed from NotI + (±)-15; (C) Product formed from 
NotI′ + (±)-15. 
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Figure 2-24. LC-MS Q-TOF analysis depicting EICs of (a) NotI′ reaction with (±)-18; (b) NotI reaction with (±)-18; 
(c) authentic (±)-18 standard. Product(s) formed is denoted with P. Asterisk denotes possible diastereomer of 18. 
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Figure 2-25. Mass spectra of (A) (±)-18 standard; (B) Product formed from NotI + (±)-18; (C) Product formed from 
NotI′ + (±)-18. 
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Figure 2-26. 
1
H NMR spectrum of Notoamide T9 (19) recorded at 700 MHz (in DMSO-d6) 
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Figure 2-27. 
13
CNMR spectrum of Notoamide T9 (19) recorded at 700 MHz (in DMSO-d6) 
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Figure 2-28. HSQCAD spectrum of Notoamide T9 (19) recorded at 700 MHz (in DMSO-d6) 
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Figure 2-29. gCOSY spectrum of Notoamide T9 (19) recorded at 700 MHz (in DMSO-d6) 
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Figure 2-30. gHMBCAD spectrum of Notoamide T9 (19) recorded at 700 MHz (in DMSO-d6) 
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Figure 2-31. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 8; (b) authentic 8 standard. Product(s) formed is denoted with P. 
  
  
65 
 
 
Figure 2-32. Mass spectra of (A) 8 standard with 3 
13
C label; (B) Product formed from PhqK + 8. 
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Figure 2-33. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 9; (b) authentic 9 standard. Product(s) formed is denoted with P. 
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Figure 2-34. Mass spectra of (A) 9 standard; (B) Product formed from PhqK + 9. 
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Figure 2-35. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 10; (b) authentic 10 standard. Product(s) formed is denoted with P. 
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Figure 2-36. Mass spectra of (A) 10 standard with 2 
13
C label; (B) Product formed from PhqK + 10. 
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Figure 2-37. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 15; (b) authentic 15 standard. Product(s) formed is denoted with P. 
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Figure 2-38. Mass spectra of (A) 15 standard; (B) Product formed from PhqK + 15. 
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Figure 2-39. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 20; (b) authentic 20 standard. Product(s) formed is denoted with P. 
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Figure 2-40. Mass spectra of (A) 20 standard; (B) Product formed from PhqK + 20. 
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Figure 2-41. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 21; (b) authentic 21 standard. Product(s) formed is denoted with P. 
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Figure 2-42. Mass spectra of (A) 21 standard with 2 
13
C label; (B) Product formed from PhqK + 21. 
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Figure 2-43. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 22; (b) authentic 22 standard. Product(s) formed is denoted with P. 
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Figure 2-44. Mass spectra of (A) 22 standard; (B) Product formed from PhqK + 22. 
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Figure 2-45. LC-MS Q-TOF analysis depicting EICs of (a) PhqK reaction with 23; (b) authentic 23 standard. Product(s) formed is denoted with P. 
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Figure 2-46. Mass spectra of (A) 23 standard; (B) Product formed from PhqK + 23. 
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Figure 3-1. Indole ring and two types of prenyl modifications. 
 
 
 
 
 
    Chapter 3 
3 Prenyltransferases 
 
3.1 Introduction 
 
 Prenylated natural compounds have demonstrated great utility in biological activity due 
to the increased lipophilicity of the molecule after modification.
108
 While the core, unmodified 
molecule may not exhibit activities of interest, prenylated molecules have been found to be 
active in most fields of pharmalogical sciences.
109
 Consequently, a better biochemical 
understanding of the mechanism of prenylation is desired. We seek to both understand the 
natural role of the prenyltransferase in the biosynthetic pathway, as well as exploring the 
prenyltransferases’ ability to modify related compounds for the diversification of natural 
products and bioactive molecules. 
Prenylated indole alkaloids comprise one class of natural products that contain a 
prenylated aromatic moiety. These compounds are typically found in Claviceps, Penicillium, and 
Aspergillus strains.
12
 The aromatic precursor is modified by an indole prenyltransferase, one 
major category of prenyltransferases that can be further divided into four major subcategories. 
Firstly, these prenyltransferases have been found to catalyze reactions on carbon atoms or 
nitrogen atoms, respectively named C- or N-prenyltransferases. Secondly, either the C1 or C3 
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atom of dimethylallyl pyrophosphate (DMAPP) will attach to the aromatic moiety, referred to as 
a regular or reverse prenylation, respectively (Figure 3-1).
110
 For example, if the regular prenyl 
moiety were added to the indole ring at position 2, it would be referred to as a regular C2-
prenylation event. Examples of each type of reaction are observed within the prenylated indole 
alkaloid family at various positions along the indole ring, suggesting that nature has evolved 
many prenyltransferases for specific modifications to the indole ring. 
The precursor molecule DMAPP also arises by its own biosynthetic pathway. While 
DMAPP is used almost universally as the building block for prenyltransferases to modify the 
indoles, it is more commonly known as the building block for the formation of isoprenoids, 
compounds that are found in all domains of life.
111
 For about the past half century, the molecule 
was believed to be formed via the mevalonic acid (MVA) pathway, which ultimately results in 
the formation of isopentenyl diphosphate (IPP) that is isomerized to DMAPP.
112
 More recently, a 
second pathway, the methylerythritol phosphate (MEP) pathway, was discovered to also generate 
IPP and DMAPP.
113
 The MEP pathway is more frequently observed in eubacteria, green algae, 
and higher plants, while the MVA pathway is more commonly observed in animals, plants, fungi, 
and archaea.
114,115
 These molecules are thus present in most domains of life. 
Indole prenyltransferases are similar to dimethylallyl tryptophan synthases from fungi, 
and include examples from Aspergillus fumigatus.
116
 Of the well characterized examples include 
 
Figure 3-2. The classical mevalonate (MVA) pathway to form IPP and DMAPP. 
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FgaPT2, a dimethylallyltryptophan synthase responsible for the C4 prenylation of trypophan in 
fumigaclavine C biosynthesis.
117
 The structure of FgaPT2 has also previously be solved, 
demonstrating its similarity to ABBA bacterial prenyltransferases,
118
 which was not readily 
apparent from the amino acid sequence.
119
 FgaPT1 has additionally been characterized as a 
reverse prenyltransferase at the C2 position of the indole ring, thus converting fumigaclavine A 
to fumigaclavine C.
120
 From the same producing organism, prenyltransferases from the 
fumitremorgin biosynthetic pathway were also biochemically characterized. FtmPT1 was found 
to prenylate the indole ring of brevianamide F at the C2 position,
121
 while FtmPT2 was 
demonstrated to perform a late biosynthetic step on fumitremorgin C, prenylating the indole ring 
on the nitrogen atom.
122
 Other fungal prenyltransferases to note include AnaPT,
123
 which 
 
Figure 3-3. Examples of known prenyltransferases and the positions they modify 
along the indole ring. Actual substrate structures are not shown for simplicity. 
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modifies the C3 position on the indole ring to form aszonalenin, and TdiB,
124
 which reverse 
prenylates the C2 position on the indole ring to form asterriquinone C-1. 
We have also previously investigated a number of prenyltransferases from the 
biosynthetic gene clusters mined in our laboratory. From the notoamide biosynthetic system, 
NotC and NotF have previously been characterized as a regular prenyltransferase at the C7 
position and a reverse prenyltransferase at the C2 position on the indole ring, respectively.
96
 
Additionally, a random prenyltransferase (MaPT) had been identified and characterized from the 
malbrancheamide pathway.
125
 This gene product was mined randomly from the sequenced 
genome before a comparative analysis of the fungal gene clusters was available. MaPT was 
determined to be a regular C-prenyltransferase at the 4 position on the indole ring, which 
curiously does not appear in the formation of the malbrancheamide natural product at all. Also 
worthy to note, MaPT was reportedly inhibited by the presence of EDTA, which is an 
 
Figure 3-4. Malbrancheamide gene cluster. 
 
Table 3-1. Predicted functions of gene products from the 
malbrancheamide gene cluster. 
Gene product Function Size (AA) 
MalA Halogenase 667 
MalB Prenyltransferase 369 
MalC Short chain dehydrogenase 264 
MalD Negative regulator 336 
MalE Prenyltransferase 438 
MalF Oxidoreductase 590 
MalG NRPS 2345 
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unexpected finding in this class of enzymes. 
When we initially investigated the malbrancheamide gene cluster (Figure 3-4), we 
identified two putative prenyltransferases: MalB and MalE (Table 3-1).
97
 Bioinformatic analysis 
of each putative gene product gave no further insight to whether these gene products were 
regular or reverse prenyltransferases, or exactly how each would compare to the 
prenyltransferases from the notoamide or paraherquamide gene clusters. The inability to 
determine the exact reaction of a fungal prenyltransferase from the amino acid sequence has been 
observed in other examples,
119
 unlike findings in bacterial prenyltransferases.
126
 Therefore, we 
decided upon an in-depth biochemical characterization of each gene product to determine the 
activity of MalB and MalE. Initial attempts to express and purify MalB and MalE resulted in 
insoluble MalB protein and soluble MalE protein. Thus, MalE was initially chosen for 
investigation due to its ease of accessibility.  
Lastly, we hypothesized that upon prenylation of the compound 3 (Figure 3-6), the 
azadiene and prenyl dienophile would react to undergo the Diels-Alder construction of 
premalbrancheamide. To date, a natural enzyme catalyst of the Diels-Alder reaction has not yet 
been identified, although artificial Diels-Alderases have been designed and engineered to be 
effective biocatalysts for the [4+2] cycloaddition reaction.
127
 However, the isolation of only the 
syn-isomers of malbrancheamide from M. aurantiaca strongly suggest that a stereoselective 
mechanism is involved in the IMDA construction of the bicyclo[2.2.2]diazaoctane core,
25
 and 
that a biosynthetic enzyme is responsible for the control of the chiral center being formed.
128
 
Therefore, we decided to investigate the activity of MalE not only as a prenyltransferase but also 
as a potential Diels-Alderase. 
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Figure 3-5. (A) Observed in vitro reaction containing MalE, DMAPP, and Brevianamide F. (B) HPLC traces 
depicting (a) Brevianamide F in reaction with MalE and (b) Brevianamide F in reaction with no enzyme. 
3.2 Results 
3.2.1 MalE demonstrates prenyltransferase activity 
 
Before we began synthesizing putative substrates for use with MalE, we decided to turn to 
already available substrates from the Notoamide pathway. NotF has been shown to reverse 
prenylate Brevianamide F to form product Deoxybrevianamide E.
96
 Assuming that MalE 
performs the same reaction, we decided to test the activity in vitro with Brevianamide F as a 
substrate that mimics the native substrate. Deoxybrevianamide E product formation was 
observed after analysis with LC-MS, demonstrating that MalE was an active enzyme that 
accepted DMAPP as a cofactor in its prenyltransferase reaction (Figure 3-5). 
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Figure 3-6. Predicted prenyltransferase reaction yielding premalbrancheamide (6) 
 
3.2.2 MalE substrate synthesis 
 
In order to validate this sequence of events, my collaborators and I have pursued a biomimetic 
synthesis of premalbrancheamide. After consideration of the various approaches to forming 
premalbrancheamide, we decided that the acquisition of the intermediate 3 preceeding the 
prenylation step would be critical to our investigation of the MalE prenyltransferase. In our 
consideration of compound 3, we realized that the azadiene would require the unfavored 
tautomer. We then hypothesized that the enzyme may play a role in stabilizing the azadiene form 
and thus decided on the synthesis of compound 8. 
During the biomimetic synthesis of pre-malbrancheamide, we discovered that compound 
8 is highly unstable (See Appendix A). It rapidly degrades to form compound 9 (Figure 3-7), 
reason unknown. We hypothesize that a spontaneous oxidation of the compound occurs by 
exposure to oxygen or water, as attempts to keep the compound under neutral gas in organic 
solvent would typically slow the oxidation process. Extensive efforts were employed to maintain 
the stability of the compound, however the compound seemed to remain stable for only several 
hours at best. Taking this hurdle into account, it was decided that the in vitro reaction with MalE 
would need to be conducted as quickly as possible after the synthesis of compound 8. 
  
88 
 
 
Figure 3-7. Deprotection of compound 7 will yield putative native substrate 8, which spontaneously oxidizes to 
form 9. 
 
3.2.3 Investigation of MalE activity with biomimetic synthetic compounds  
 
Because compound 8 was found to be unstable, stable compounds 9 and 10 were provided by 
collaborators in the Williams group for preliminary testing in vitro with MalE. As expected, 
compound 10 successfully reacted to form a prenylated product. Curiously, reactions with 
 
Figure 3-8. Reactions with 10 successfully generate product 11.  HPLC traces depict (a) reaction containing 10 
and MalE enzyme and (b) reaction containing 10 and no enzyme. A slight shift in trace (b) was observed for 
substrate 10 due to possible pump error. 
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Figure 3-9. Observed enzymatic reaction containing MalE and synthesized substrate. 
 
compound 9 showed no formation of prenylated product, indicating that compound 9 is not 
accepted as a substrate by MalE for prenylation. 
3.2.4 Investigation of MalE activity with predicted native substrate 8 
 
In order to test the predicted native substrate 8, the compound would need to be generated and 
immediately tested in vitro with enzyme. To do so, the FMOC-protected compound 7 was 
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provided to our lab for deprotection following established procedures (See section 3.2.2). The 
reaction was then dried down under argon gas and resuspended in degassed DMSO to yield a 50 
mM stock solution based on the amount of starting material used. Reactions were set up 
containing 0.5 mM substrate mixture in DMSO, 0.1 mM DMAPP, and 50 uL MalE in degassed 
phosphate reaction buffer for a total reaction volume of 500 uL. Reactions were conducted on 
benchtop under vacuum gas and extracted after 1 hour. The analysis was conducted by LC-MS, 
and the results are depicted in Figure 3-9. 
Prenylation was observed for unstable synthetic substrate 8. However, the prenylated 
product oxidized to generate the major product 13 as observed by LC-MS (Figure 3-10). 
Consequently, no premalbrancheamide was observed to be formed from reactions containing 
MalE and 8. According to the biomimetic synthesis (Appendix A: Error! Reference source not 
ound.), upon prenylation to produce the observed minor product, treatment with TFA should 
push formation of premalbrancheamide. The synthesis and enzymatic prenylation was thus 
repeated, followed by addition of TFA to the reaction mixture to simulate biomimetic synthetic 
procedures. Formation of premalbrancheamide was not observed from these reactions. 
Additionally, reactions were carried out under various pH conditions between 4.0 and 10.0, with 
no observable premalbrancheamide formation. 
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3.3 Discussion 
 
 MalE, a putative prenyltransferase identified in the malbrancheamide biosynthetic gene 
cluster, was determined to be an active protein able to prenylate not only its expected substrate 
monooxopiperazines but also some dioxopiperazines from the notoamide pathway. From the 
observed in vitro reactions, MalE is able to use DMAPP to prenylate various indole alkaloid 
derivatives in a similar fashion to NotF from the notoamide pathway.
96
 The only substrate that 
was not accepted by MalE for reaction was compound 9, the oxidized form of the predicted 
native substrate. 
 
Figure 3-10. Reactions containing 8. HPLC traces of (a) authentic premalbrancheamide standard, (b) MalE with 
synthetic product 8, (c) synthetic product 8 (seen as 9) from deprotection of 7, and (d) 7 standard. 
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 We were expecting the IMDA reaction to occur upon introduction of the prenyl 
dienophile. Based on previous investigations of Diels-Alder biosynthetic enzymes, we predicted 
that MalE would similarly act as a chaperone-like protein, providing a scaffold to lower the 
activation energy of the IMDA reaction. Instead, the data suggest that MalE catalyzes a 
prenylation reaction and releases the prenylated product. Interestingly, the lack of 
premalbrancheamide formation suggests that an additional catalyst may be needed for the IMDA 
reaction to occur. In other words, the lack of spontaneous cyclization supports the theory that a 
biocatalyst is needed for the Diels-Alder reaction, and that a different enzyme may be involved 
in this step of malbrancheamide biosynthesis. These findings are presented in contrast to the 
formation of spinosyn A, which forms with or without enzyme but increases catalytic activity in 
presence of enzyme.
80
 On the other hand, it is possible that the IMDA reaction in 
malbrancheamide biosynthesis is instead dependent upon the biosynthetic enzyme for catalysis 
and will not proceed without it. 
 It is important to note that the identity of the product being formed was only verified 
using LC-MS experiments. An authentic synthetic standard of 13 was provided and analyzed for 
comparison, demonstrating that the compound generated from in vitro reactions containing MalE 
and 8 was indeed 13 (data not shown). However, if this investigation is to be continued, it would 
be highly advised to obtain structural data for the product compound to determine whether the 
prenyltransferase reaction is indeed a reverse prenylation at the C2 position of tryptophan. It is 
unclear the degree to which the retention times may differ if the prenylation reaction occurred at 
a different position, or if the prenylation reaction occurred in the normal direction. Therefore, the 
exact product being formed by MalE has not yet been investigated to 100% certainty. 
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  As the investigation for the Diels-Alderase continues, we have begun to turn to other 
biosynthetic enzymes present within the gene cluster. The instability of compound 8 suggests 
that it is unlikely to exist as an intermediate within the organism. This finding suggests a few 
options could be viable: (a) the prenylation event occurs before tryptophan is loaded onto the 
 
Figure 3-11. Alternative order of biosynthesis where prenylation occurs before loading onto the NRPS. 
 
 
Figure 3-12. Alternative order of biosynthesis where a separate enzyme is responsible for the stabilization of the 
prenylated intermediate and Diels-Alder reaction. 
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NRPS (Figure 3-11) or (b) a separate protein is responsible for stabilizing the intermediate 
(Figure 3-12). In the former case, the NRPS MalG would be acting as the Diels-Alderase, and 
the prenyl dienophile is introduced before the azadiene is formed. In the latter case, the protein 
may be acting as a chaperone or scaffold to stabilize the intermediate, or it could be interacting 
with prenyltransferase MalE to perform the IMDA reaction.  
 In summary, we have identified the biochemical activity of MalE, a prenyltransferase 
from the malbrancheamide biosynthetic gene cluster. MalE is able to prenylate dipeptides similar 
to and including brevianamide F, appearing to catalyze the same reaction as NotF from the 
notoamide pathway. This body of work was conducted in order to address our hypothesis that the 
IMDA reaction occurs immediately after prenylation in the malbrancheamide pathway. The 
collected evidence do not support the hypothesis that MalE can form the IMDA product, 
premalbrancheamide. However, the lack of premalbrancheamide formation also suggests that a 
separate catalyst may be necessary for the Diels-Alder reaction. In future work, MalE will be 
investigated alongside the remaining malbrancheamide biosynthetic enzymes for its possible role 
in IMDA synthesis. Overall, the findings in this investigation have puzzling yet exciting 
implications for bicyclo[2.2.2]diazaoctane biosynthesis. 
 
3.4 Methods 
 
1. Fungal strains and culture conditions 
Malbranchea aurantiaca spores were generated on YPD agar plates over the course of 7 days. 
Spores were harvested into 5 mL sterile water per plate by gently scraping the surface of the 
culture with a sterile inoculating loop. Spores were stored at -80°C until ready to use. Genomic 
DNA was harvested using Wizard Genomic DNA Purification Kit from Promega. 
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2. cDNA preparation and cloning of malE 
Total RNA was extracted from a sample of fungal mycelia collected on the 15th day of culture 
grown in liquid medium (Difco Potato Dextrose Broth) with 160 rpm agitation at 28°C, using 
Invitrogen PureLink RNA Mini Kit by following the plant tissue processing protocol. RNA was 
treated using DNase I. cDNA was generated using Invitrogen Superscript First Strand Synthesis. 
PCR was used to amplify malE from the cDNA template. The amplified gene was then cloned 
into pET28b vector using restriction enzyme digest and ligation. Plasmids were transformed into 
E. coli DH5α for screening and plasmid maintenance. 
 
3. Overexpression and purification of protein for enzymology 
The Escherichia coli BL21 pRARE transformant containing pET28b-malE was grown at 37°C 
overnight in LB media containing 50 µg/mL of kanamycin and 100 µg/mL of spectinomycin. 25 
mL of culture was used to inoculate 1 L of TB media containing the aforementioned 
concentrations of antibiotic and 4% glycerol. Cells were grown at 37°C for roughly 4 hours until 
A600 reached 0.6-1.0, and isopropyl β-D-thiogalactoside (IPTG, 0.2 mM) was added to induce 
protein overexpression overnight at 18°C. 
 
All purification steps were conducted at 4°C. Briefly, 2 L of expression culture were spun down 
at 5,500 xg to yield approximately 20 mL of cell pellet volume. Harvested cell pellets were 
resuspended in 60 ml of lysis buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% 
v/v glycerol, pH 8) and lysed by sonication. Insoluble material was removed by centrifugation at 
38,000 xg for 30 min, and the supernatant was batch-bound for 1 hour to 4 mL of Ni
2+
-NTA 
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slurry (Novagen) that was equilibrated in lysis buffer. This batch-binding mixture was poured 
through a 50 ml fritted glass column where the retained resin was washed with 100 mL of lysis 
buffer, 50 mL of wash buffer (20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% v/v 
glycerol, pH 8), and finally 10 ml of elution buffer (250 mM imidazole, 50 mM NaH2PO4, 300 
mM NaCl, 10% v/v glycerol, pH 8). Protein in the eluate was exchanged into storage buffer (50 
mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 7.3) using PD-10 columns. 
Samples were then flash frozen with liquid N2 and stored at -80°C. 
 
4. Enzyme assays and LC-MS analysis 
The standard enzyme assay containing 0.5 mM substrate mixture in DMSO, 0.1 mM DMAPP, 
and 50 uL MalE in 500 µL total volume reaction buffer  (50 mM NaH2PO4, 1 mM EDTA, 0.2 
mM DTT, 10% v/v glycerol, pH 7.3) was performed on benchtop under vacuum for one hour. 
100 uL of each reaction was then transferred to a new eppendorf tube, extracted 3 times with 200 
µL chloroform, and the extract was dried down under N2 gas. The product was then resuspended 
in 100 µL methanol for LC-MS Q-TOF analysis. Analysis was conducted on a LCMS-2010 EV 
outfitted with a Waters XBridge C18 3.5 μm, 2.1x150 mm column. HPLC conditions: 
monitoring wavelengths 240 nm and 280 nm; scanning 200 to 1200 m/z; solvent A: water + 0.1% 
formic acid, solvent B: acetonitrile + 0.1% formic acid; flow rate: 0.2 mL/min; mobile phase: 20% 
B over 2 min, 20-100% B over 10 min, 100% B over 5 min, 100-20% B over 1 min, 20% over 7 
min. 
 
3.5 Appendix A* 
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*Adapted from manuscript in progress written by James D. Sunderhaus, Jennifer M. Finefield, 
Amber D. Somoza, Timothy J. McAfoos, Hong Tran, David H. Sherman, and Robert M. 
Williams. 
Chemical validation of the proposed IMDA construction of monooxopiperazine prenylated 
indole alkaloids. 
The ever expanding family of prenylated indole alkaloids produced by various genera of fungi, 
has attracted considerable interest due to their wide spectrum of biological activities, and serve 
as provocative targets for chemical synthesis and biosynthetic studies.
10
 Family members include 
the anticancer agents stephacidin A,
32
 the anthelmintic paraherquamide A,
129
 calmodulin-
inhibitor malbrancheamide,
51
 neuroprotective agent chrysogenamide A among a growing number 
of related novel bioactive metabolites.
10
 
Of particular interest to our laboratories, is the mechanism by which Nature constrcucts the 
bicyclo[2.2.2]diazaoctane ring nucleus that is common to this family of prenylated indole 
alkaloids. It is noteworthy that, the paraherquamides, asperparalines, malbrancheamides, 
marcfortines and chrysogenamide A, are all constituted of a monooxpiperazine-based 
bicyclo[2.2.2]diazaoctane system, whereas the stephacidins, notoamides, brevianamides, 
aspergamides, and avrainvillamide, are all constituted of a dioxopiperazine-based 
bicyclo[2.2.2]diazaoctane system. Structures of a few representative members of both sub-
families are depicted in Figure 3-13. The unique bicyclo [2.2.2] diazaoctane core of these 
naturally occurring fungal metabolites, has been proposed to arise from an intramolecular Diels-
Alder (IMDA) reaction. An additional fascinating element in the biosynthesis of the notoamides 
and stephacidins is the discovery that the marine-derived Aspergillus sp. MF297-2 exclusively 
produces the enantiomers of (+)-stephacidin A, and (-)-notoamide B, whereas the terrestrial A. 
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versicolor NRRL 35600 generates the antipodal products (-)-stephacidin A, and (+)-notoamide B. 
This implies the biosynthetic enzymes involved in assembly and tailoring might have evolved to 
catalyze an “identical” reaction to give an enantiomerically distinct product.  
 
 
Figure 3-13. Representative fungal prenylated indole alkaloids. 
The monooxopiperazine-based members of this family, such as paraherquamide and 
malbrancheamide, have been the subject of intensive study in our laboratories with respect to the 
identification of early pathway metabolites that contain the bicyclo[2.2.2]diazaoctane ring 
system. In both the case of paraherquamide and malbrancheamide biosynthesis, we have 
synthesized the double 
13
C-labeled putative progenitors “pre-malbrancheamide” and “pre-
paraherquamide”. In both instances, precursor incorporation experiments with the respective 
producing fungi, revealed that both “pre-malbrancheamide” and “pre-paraherquamide” were 
incorporated intact into malbrancheamide B and paraherquamide A, respectively. Curiously, in 
both instances, the synthetic, double 
13
C-labeled dioxopiperazines from which “pre-
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malbrancheamide” and “pre-paraherquamide” were prepared by recution of the tryptophan-
derived carbonyl group, were found not to incorporate into the respective natural products in 
parallel precursor incorporation experiments as illustrated in Scheme 3-1. This raised the obvious 
question as to the timing of the reduction of the tryptophan-derived carbonyl group, by a net 
four-electrons, down to the oxidation state of a CH2 group as this position exists in the natural 
products. 
 
Scheme 3-1. Precursor incorporation experiments of monooxpiperazine and dioxopiperazine substrates. 
To address these biosynthetic questions, we recently sequenced the genome of Penicillium 
fellutanum and Malbranchea aurantiaca and identified the malbrancheamide and 
paraherquamide biosynthetic gene clusters through in silico sequence database mining.
97
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found that in both the malbrancheamide and paraherquamide NRPS modules, the terminal end of 
the tryptophan unit, is constituted with a reductase domain, as opposed to a condensation domain 
which is evident in the stephacidin and notoamide biosynthetic geneclusters. This remarkable 
finding led us to suggest that the bicyclo[2.2.2]diazaoctane ring system is directly produced in 
the monooxopiperazine oxidation state, via the cascade of events depicted in Scheme 3-2, 
following the reductive cleavage of the tryptophan thiol ester by the NADPH-dependent 
reductase domain. Although we do not yet know the exact timing of the reverse prenylation, all 
available evidence suggests that the most likely sequence is at the stage of one of the reduced 
dipeptide intermediates (5-8).  
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Scheme 3-2. Biomimetic synthesis of pre-malbrancheamide. 
In order to validate this sequence of events, we have prepared amino-aldehyde 5 (R=H), and 
have found that this substance spontaneously undergoes the cascade of ring closure (6), 
dehydration (7), tautomerization (8) and intramolecular Diels-Alder cycloaddition to give pre-
malbrancheamide as an isolable product as illustrated in Scheme 3-3. 
The key, Fmoc-protected amino aldehyde (13), corresponding to putative species 5 was 
prepared through the peptide coupling of N-Fmoc proline (10) with the C2-reverse-prenylated 
tryptophan methyl ester (9) through the agency of HATU in acetonitrile in 85% yield. Reduction 
of the methyl ester with sodium borohydride (82% to 12) followed by a Doering-LaFlamme 
oxidation, furnished the N-Fmoc aldehyde 13 in 72% yield. Removal of the N-Fmoc residue with 
diethylamine furnished the di-enamine 7, which could be isolated and characterized. Treatment 
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of this substance with TFA in THF at temperatures between 0 
o
C and 50 
o
C, resulted in the 
formation of pre-malbrancheamide, and the unexpected carbinolamine oxidation congener 14 as 
a minor product. At 50 
o
C, pre-malbrancheamide was produced in an 8:1 ratio with 14 
(inseparable) in 40% combined yield.  
  As further proof to our proposal, we applied an analogous synthesis to an additional 
member of the malbrancheamide family, spiromalbramide (23). Likewise, the key halogenated 
Fmoc-protected amino aldehyde (20) was prepared by peptide coupling of the reverse prenylated 
tryptophan ethyl ester (16) with Fmoc-protected proline amino acid (17) using HATU afforded 
an 87% yield. The ethyl ester was reduced with sodium borohydride (19 in 90%) and followed 
by an oxidation to provide the N-Fmoc aldehyde 20 in 89% yield. The Fmoc group was removed 
with diethylamine, and the crude product was directly treated with a degassed solution of TFA in 
THF at room temperature to provided the syn cycloadduct of malbrancheamide (21) in 38% 
yield.  Malbrancheamide was treated with N-chlorosucinimide to form the chloroindoline 
intermediate (22), which was directly hydrated under acidic conditions to undergo a pincol-type 
rearrangement and form spiromalbramide in 13% yield. 
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Scheme 3-3. Biomimetic synthesis of spiromalbramide. 
 We presume in the biosynthesis of pre-malbrancheamide, that it is the reverse-
prenyltransferase, that likely catalyzes the tautomerization and intramolecular Diels-Alder 
reaction of the putative azadiene 8, which in the case of pre-malbrancheamide, is achiral. The 
fact that malbrancheamide and malbrancheamide B are produced as single, optically pure 
enantiomers, provocatively suggests that the reverse-prenyltransferase, must orient the azadiene 
and pendant isoprene-derived vinyl residue in a single conformational disposition that 
concomitantly controls the enantiofacial bias and the diasteroselectivity of this cycloaddition that 
proceeds to give only the syn-stereochemistry. 
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3.6  Appendix B 
 
 
Figure 3-14. Mass spectrum of substrate 10 with [M+H] peak at 270.05 m/z. 
 
Figure 3-15. Mass spectrum of product 11 with [M+H] peak at 338.00 m/z. 
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Figure 3-16. Mass spectrum of compound 9 with [M+H] peak at 265.80 m/z. 
 
Figure 3-17. Mass spectrum of compound 7 with [M+H] peak at 508.15 m/z. 
 
Figure 3-18. Mass spectrum of deprotected 7 appears as 9 with [M+H] peak at 266.00 m/z. 
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Figure 3-19. Mass spectrum of compound 12 with [M+H] peak at 336.00 m/z. 
 
Figure 3-20. Mass spectrum of compound 13 with [M+H] peak at 334.10 m/z. 
 
Figure 3-21. Mass spectrum of standard premalbrancheamide 6 with [M+H] peak at 336.10 m/z. 
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     Chapter 4 
4 Halogenation 
 
4.1 Introduction 
 
Halogenated natural products have demonstrated great utility as antibiotics, including the 
well-known vancomycin and chloramphenicol.
130,131
 In regards to the importance of the halogens, 
the two chlorine substituents on vancomycin, for example, are required for clinical activity of the 
compound.
132
 Today, this vast group of naturally occurring organohalogens exceeds 5000 in 
number, with roughly 25% of that number being constituted of halogenated alkaloids.
133
 In terms 
of origin, the compounds are produced by bacteria, fungi, lichens, marine algae, higher plants, 
insects, invertebrates, vertebrates, and mammals, demonstrating the wide spread of halogenases 
in nature.
55
 Chlorinated compounds are frequently observed in terrestrial environments, while 
brominated compounds are abundant in the marine environment, and fluorinated compounds are 
incredibly rare.
134
 Halogenases are typically found to be able to perform both chlorination or 
bromination reactions, and the incorporation of chlorine versus bromine is usually dependent 
upon which halogen is supplied by the environment or medium of the organism.
135
 
Halogenases can currently be divided into five major categories: heme iron-dependent 
haloperoxidases, vanadium-dependent halo peroxidases, flavin-dependent halogenases, non-
heme iron-dependent halogenases, and nucleophilic halogenases.
56
 While haloperoxidases were 
previously believed to be the primary halogenase enzymes, research in the field has led us to the 
understanding that naturally halogenated compounds are more often produced by flavin-
dependent halogenases.
136
 These flavin-dependent halogenases are also dependent upon a flavin 
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reductase for the supply of reduced flavin necessary to conduct its halogenation reaction.  Of 
these flavin-dependent halogenases, they can be further subdivided into two major groups: 
enzymes that halogenate small-molecule substrates and enzymes that react with substrates bound 
to the thiolation of an NRPS system.
137
 For halogenating indoles, tryptophan halogenases are 
included in the former of the two categories and have been well-characterized, including but not 
limited to rebeccamycin’s RebH138,139 and pyrrolnitrin’s PrnA140,141. PyrH and ThaI round out the 
other tryptophan halogenases that chlorinate at the C5 and C6 positions, respectively (Figure 
4-1).
57,142
 
In the malbrancheamide natural product, we observe two chlorine atoms at the C5 and C6 
positions on the tryptophan moiety.
17
 Additionally, the two monochlorinated intermediates 
 
Figure 4-1. Characterized tryptophan halogenase reactions. 
 
 
Figure 4-2. Results from incorporation studies using isotopically labeled premalbrancheamide. 
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malbrancheamide B and isomalbrancheamide B have also been isolated and identified by the 
Mata group.
53,143
 Previous studies in our lab have shown that isotopically labeled 
premalbrancheamide fed to the producing organism Malbranchea aurantiaca will result in the 
production of labeled malbrancheamide B, but no production of labeled malbrancheamide 
(Figure 4-2).
62
 These findings suggested that perhaps the second chlorination event happened 
much slower than the first, and thus no observation of dichlorinated product was seen. Later, the 
genome of the producing organism Malbranchea aurantiaca was sequenced and mined to 
identify putative gene clusters containing biosynthetic genes.
97
 These data were used to identify a 
putative tryptophan halogenase MalA involved in the generation of malbrancheamide via 
BLAST analysis. We thus hypothesized that MalA would be responsible for the both 
chlorinations of the indole ring on premalbrancheamide. Further analysis of the protein sequence 
via BLAST revealed alignment with conserved domains of tryptophan halogenase proteins and 
possibly also the Lys79 residue (observed at Lys78) known to direct chlorination on tryptophan 
(Figure 4-14), further supporting our identification of the halogenase in the malbrancheamide 
biosynthetic pathway.
140,144
  
In this investigation, we sought to biochemically determine the role of MalA as the only 
identified putative halogenase in the gene clusters of the bicyclo[2.2.2]diazaoctanes. Because no 
other molecule in the prenylated indole alkaloid family contains halogens, we were particularly 
interested in elucidating the timing and chemistry of the halogenation event within the 
malbrancheamide pathway. Additionally, we were curious whether the halogenase would play a 
part in the IMDA reaction, since its predicted function would occur immediately after or 
concurrently with the formation of the bicyclo[2.2.2]diazaoctane core. In other words, there was 
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a possibility that the halogenase could receive the Diels-Alder substrate and mold the molecule 
into the correct conformation for an IMDA reaction before or while performing its halogenation. 
4.2 Results 
4.2.1 Determination of MalA as a flavin-dependent halogenase and malbrancheamide 
synthase 
 
The function of MalA as a putative flavin-dependent halogenase was investigated. The in vitro 
activity of MalA was tested in reactions containing tryptophan, premalbrancheamide, 
malbrancheamide B, and isomalbrancheamide B. Additionally, flavin reductase HpaC was used 
to supply reduced flavin to MalA in vitro.
145
 Malbrancheamide B and isomalbrancheamide B 
were reacted to form malbrancheamide ([M+H]: 404.10 m/z). On the other hand, 
premalbrancheamide did not react with MalA to form any of the chlorinated compounds (i.e. 
malbrancheamide B, isomalbrancheamide B, or malbrancheamide). This was an unexpected 
result, as we began this investigation with preliminary evidence supporting the formation of 
malbrancheamide B from premalbrancheamide. 
 
Figure 4-3. Chlorination reactions on malbrancheamide B and 
isomalbrancheamide B produce malbrancheamide using MalA. 
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4.2.2 MalA performs bromination reactions when using bromide as a source ion 
 
Since most halogenases are also able to perform bromination reactions, we decided to investigate 
MalA’s potential in modifying malbrancheamide B and isomalbrancheamide B with bromine 
atoms. Thus, we performed similar reactions using NaBr instead of NaCl in solution. As 
expected, we were able to observe a brominated compound for each reaction with an observed 
[M+H] peak at 448.00 m/z. These reactions should thus be forming two new compounds 
depending on which substrate was used for the reaction (Figure 4-4). For my dissertation, I have 
temporarily assigned the names malbrancheamide D and isomalbrancheamide D to these 
compounds, as they do not yet have formal names. 
 
Figure 4-4. Bromination reactions on malbrancheamide B and 
isomalbrancheamide B produce malbrancheamide D and isomalbrancheamide 
D using MalA. 
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Figure 4-5. HPLC traces of reactions using MalA and malbrancheamide B. HPLC traces depict (a) negative 
control reaction with no enzyme, (b) reaction + MalA + NaCl, (c) reaction + MalA + NaBr. 
 
 
 
Figure 4-6. Traces of reactions containing MalA and isomalbrancheamide B. HPLC traces depict (a) negative 
control reaction with no enzyme, (b) reaction + MalA + NaCl, (c) reaction + MalA + NaBr. 
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4.3 Conclusion 
 
In conclusion, MalA was found to be responsible for the second chlorination event, but it 
unexpectedly plays no part in the first chlorination event. This finding more or less eliminates 
MalA from being a candidate for the IMDA reaction, as it would accept a substrate later in the 
biosynthetic pathway. Strangely, the data also would imply that a second halogenase, likely 
halogenating premalbrancheamide based on isotopic feeding studies, is involved in the 
biosynthesis of malbrancheamide, but no second halogenase has been identified in or near the 
gene cluster. As an alternative option, we did not investigate the potential interaction between the 
halogenase and the NRPS module due to not having active NRPS, as halogenases are also known 
to react with substrates tethered to their peptidyl or acyl carrier proteins.
136
 
 
Scheme 4-1. Adjusted malbrancheamide biosynthetic pathway based on MalA investigation results. 
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 We were excited to see that MalA would be able to perform the bromination reactions, 
thus resulting in two new malbrancheamide compounds with a hybrid halogen modification on 
 
Figure 4-7. Currently discovered malbrancheamides with different 
halogen modifications. 
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the indole ring. The result is in agreement with the literature in that flavin halogenases are able to 
perform bromination reactions in addition to chlorination reactions.
146
 Interestingly, only the 
single brominated compounds, malbrancheamide C (7) and isomalbrancheamide C (8), have 
been isolated previously from related fungus M. graminicola when grown in medium containing 
bromide ions (Figure 4-7).
84
 Comparison of the two gene clusters from M. aurantiaca and M. 
graminicola show a 99% DNA sequence identity (unpublished data), suggesting that these 
compounds use identical biosynthetic pathways and that the brominated compounds could also 
be generated by the M. aurantiaca strain using the right growth conditions.  
 Investigations are currently being pursued to fully characterize the structures of 
malbrancheamide D and isomalbrancheamide D. Reactions shown here will be scaled up for 
isolation of purified product, which will then be used in 2D NMR experiments. We expect to 
find data corresponding to the structures shown here (Figure 4-3, Figure 4-4), as the collected 
mass spectrometry data support the current structures in mass and observed isotopic distribution 
patterns (see Appendix). However, while we are fairly confident in the identities of our products, 
we are unable to say with certainty that the structures of malbrancheamide D and 
isomalbrancheamide D are correct until we have gathered the necessary NMR data. 
 We aim to examine the ability of MalA to halogenate related molecules from the 
bicyclo[2.2.2]diazaoctane fungal alkaloid family of compounds. With our current data, it is 
impossible to judge the potential of MalA as a tool in biotechnology for performing halogenation 
reactions. However, related investigations have been performed using RebH from the 
rebeccamycin pathway, suggesting that the investigation of MalA as a biocatalyst would merit 
similar intrigue. RebH has thus far been shown to be able to halogenate arenes,
139
 reengineered 
to halogenate tryptamine instead of tryptophan,
59
 and improved for better stability and catalytic 
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lifespan.
147
 Therefore, we are interested in employing a similar approach to engineer and utilize 
MalA as a biocatalyst for generating new compounds of interest. 
 In summary, we have elucidated the activity of MalA, a predicted FAD-dependent 
halogenase from the malbrancheamide biosynthetic pathway. The enzyme is a welcome addition 
to the current scarcity of identified eukaryotic halogenases, including the DIF-1 halogenase from 
Dictyostelium discoideum
148
 and fungal halogenase Rdc2 from Pochonia chlamydosporia.
149
 
MalA accepts both substrates malbrancheamide B and isomalbrancheamide B for chlorination or 
bromination reactions. The curiously flexible binding pocket and the necessity of the initial 
chlorine substituent will be further investigated using crystallography by our collaborators in the 
Smith group. We are excited to report the new compounds malbrancheamide D and 
isomalbrancheamide D once we have more thorough data to support our hypothesis. MalA is the 
first of our malbrancheamide enzymes that we have thoroughly characterized, and this 
investigation expands upon our understanding of the biosynthesis of malbrancheamide as a 
member of the bicyclo[2.2.2]diazaoctane family. 
4.4 Methods 
 
1. Fungal strains and Culture Conditions 
Malbranchea aurantiaca spores were generated on YPD agar plates over the course of 7 days. 
Spores were harvested into 5 mL sterile water per plate by gently scraping the surface of the 
culture with a sterile inoculating loop. Spores were stored at -80°C until ready to use. Genomic 
DNA was harvested using Wizard Genomic DNA Purification Kit from Promega. 
 
2. cDNA preparation and cloning of malE 
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Total RNA was extracted from a sample of fungal mycelia collected on the 15th day of culture 
grown in liquid medium (Difco Potato Dextrose Broth) with 160 rpm agitation at 28°C, using 
Invitrogen PureLink RNA Mini Kit by following the plant tissue processing protocol. RNA was 
treated using DNase I. cDNA was generated using Invitrogen Superscript First Strand Synthesis. 
PCR was used to amplify malA from the cDNA template. The amplified gene was then cloned 
into a pET28b vector using restriction enzyme digest and ligation for an N-term His6 construct, 
and a pET21b vector for a C-term His6 construct. Plasmids were transformed into E. coli DH5α 
for screening and plasmid maintenance. 
 
3. Overexpression and purification of protein for enzymology 
The Escherichia coli BL21 pRARE transformant containing pET28b-malA and Takara 
chaperone pGro7 was grown at 37°C overnight in LB media containing 50 µg/mL of kanamycin 
and 100 µg/mL of spectinomycin. 25 mL of culture was used to inoculate 1 L of TB media 
containing the aforementioned concentrations of antibiotic and 4% glycerol. Cells were grown at 
37°C for roughly 4 hours until A600 reached 0.6-1.0, and isopropyl β-D-thiogalactoside (IPTG, 
0.2 mM) was added to induce protein overexpression overnight at 18°C. 
 
pET11a-phaC expression plasmid was transformed into E. coli BL21 pRARE cells for 
expression of His4-tagged HpaC reductase enzyme. 
 
All purification steps were conducted at 4°C. Briefly, 2 L of expression culture were spun down 
at 5,500 xg to yield approximately 20 mL of cell pellet volume. Harvested cell pellets were 
resuspended in 60 ml of lysis buffer (10 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% 
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v/v glycerol, pH 8) and lysed by sonication. Insoluble material was removed by centrifugation at 
38,000 xg for 30 min, and the supernatant was batch-bound for 1 hour to 4 mL of Ni
2+
-NTA 
slurry (Novagen) that was equilibrated in lysis buffer. This batch-binding mixture was poured 
through a 50 ml fritted glass column where the retained resin was washed with 100 mL of lysis 
buffer, 50 mL of wash buffer (20 mM imidazole, 50 mM NaH2PO4, 300 mM NaCl, 10% v/v 
glycerol, pH 8), and finally 10 ml of elution buffer (250 mM imidazole, 50 mM NaH2PO4, 300 
mM NaCl, 10% v/v glycerol, pH 8). Protein in the eluate was exchanged into storage buffer (50 
mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 7.3) using PD-10 columns. 
Samples were then flash frozen with liquid N2 and stored at -80°C. 
 
4. Enzyme assays and LC-MS analysis 
The standard enzyme assay containing 0.5 mM substrate, 2.5 mM NADH, and 20 µM enzyme in 
100 µL reaction buffer  (50 mM NaH2PO4, 1 mM EDTA, 0.2 mM DTT, 10% v/v glycerol, pH 
7.3) was performed at 28°C overnight. Each reaction was extracted 3 times with 200 µL 
chloroform, and the extract was dried down under N2 gas. The product was resuspended in 100 
µL methanol for LC-MS Q-TOF analysis.  
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4.5 Appendix 
 
 
Figure 4-8. Mass spectrum of malbrancheamide B (2) with [M+H] observed at 370.15 m/z. 
 
Figure 4-9. Mass spectrum of malbrancheamide product (4) from reaction with malbrancheamide B substrate. [M+H] observed at 404.10 m/z. 
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Figure 4-10. Mass spectrum of malbrancheamide D product (5) from reaction with malbrancheamide B substrate. [M+H] observed at 448.10 m/z. 
 
Figure 4-11. Mass spectrum of isomalbrancheamide B (3) with [M+H] observed at 370.15 m/z. 
 
Figure 4-12. Mass spectrum of malbrancheamide product (4) from reaction with isomalbrancheamide B substrate. [M+H] observed at 404.05 m/z. 
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Figure 4-13. Mass spectrum of isomalbrancheamide D product (6) from reaction with isomalbrancheamide B substrate. [M+H] observed at 448.05 m/z. 
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Figure 4-14. MalA protein sequence with BLAST tryptophan halogenase domain identification and Lys78 
highlighted. 
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Chapter 5 
5                                                             Future Work 
 
In the chapters of my dissertation, I have described my findings regarding three key steps in 
bicyclo[2.2.2]diazaoctane fungal indole alkaloid biosynthesis. First, we have biochemically 
characterized three flavin monooxygenases from the notoamide and paraherquamide biosynthetic 
pathways: NotI, NotI′ and PhqK. These flavin monooxygenases were found to be very flexible 
within their own systems and also were able to be used to diversify the pool of natural products 
within this class of alkaloids. Second, we investigated the role of the prenyltransferase MalE in 
the malbrancheamide biosynthetic pathway. We determined that it was an active 
prenyltransferase with some degree of flexibility for both the mono- and dioxopiperazine 
substrates. Finally, we tested the role of the MalA halogenase from the malbrancheamide 
pathway. MalA appears to only react with a malbrancheamide B and isomalbrancheamide B, 
suggesting that the other chlorine comes from a different source. 
 Our findings with NotI, NotI’, and PhqK indicate that they could be exploited as 
biocatalysts for the synthesis of new and interesting compounds. In particular, they could be used 
in a chemoenzymatic approach, combining the strengths of synthetic chemistry and biochemistry, 
to further expand the diversity of the bicyclo[2.2.2]diazaoctanes, and possibly the diversity of 
bioactivity and potency of the molecules being created. For this approach, it would be useful to 
engineer a mutated gene product that would perform as a better catalyst in a similar manner to 
the PikC mutant used in our laboratory.
150
 Perhaps the first step in future directions would be to 
identify and mutate specific residues to see how the mutations would affect activity. 
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 While we were able to confirm the prenyltransferase activity of MalE, the story led to the 
development of many new questions regarding the mechanism of the Diels-Alder reaction. We 
suggested testing various new substrates, particularly molecules that would stabilize the azadiene 
formation or molecules that would be unable to oxidize to form the aromatic ring. We were 
unable to determine whether the oxygen atom was being provided by molecular oxygen in the 
atmosphere or from water based on synthetic investigations. Based on our findings, we believe 
that there is a possibility of another enzyme being the candidate for the IMDA reaction. 
Alternatively, there could be some interaction between a pair of proteins, MalE and some other 
enzyme, that would yield the Diels-Alder product. Our fungal alkaloid collaborative team has 
discussed this question and decided that investigating the remaining biosynthetic gene products 
in the malbrancheamide gene cluster would be necessary to answering this question. 
 The investigation of MalA provided us an insightful story to the halogenation of 
malbrancheamide. Contrary to what we expected, it only performs the second halogenation event 
rather than both the first and second. Consequently, it appears as though there may be a second 
halogenase in the organism that is responsible for the first halogenation event, likely using 
premalbrancheamide as a substrate based on isotopically enriched precursor incorporation 
experiments. This study effectively eliminated the possibility of MalA being the Diels-Alderase 
under the conditions tested, since the enzyme does not accept the IMDA-related substrate. 
Additionally, we found that MalA was able to brominate malbrancheamide B and 
isomalbrancheamide B, thus producing new compounds malbrancheamide D and 
isomalbrancheamide D. 
 In summary, rather than discovering the existence of a natural Diels-Alderase, I instead 
characterized three key steps in bicyclo[2.2.2]diazaoctane biosynthesis. A continued 
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investigation of the relatively small malbrancheamide gene cluster may eventually lead to 
identification of the IMDA catalyst, assuming the catalyst responsible is an enzyme. The work 
summarized in this dissertation covers three key gene candidates, leaving four remaining from 
the malbrancheamide gene cluster to investigate. By process of elimination, we may eventually 
arrive at the identification of the Diels-Alderase. 
 Alternatively, a strategy that I had initially proposed but was not included in my thesis 
work was moving the entire gene cluster to an alternative organism to see if malbrancheamide 
could be produced. This strategy had been previously employed by the Cox group to transfer the 
tenellin biosynthetic gene cluster to A. oryzae.
151
 The heterologous reconstruction of a full 
biosynthetic gene cluster would verify that the seven genes are all that are required for the 
formation of malbrancheamide, and the approach is feasible because of the relatively small size 
of the malbrancheamide gene cluster (20 KB). Furthermore, this approach could then be used to 
generate knockouts of each putative biosynthetic gene for an alternative method to identifying 
functions of biosynthetic gene products.  
 Overall, we have made a significant contribution to our understanding of fungal indole 
alkaloid biosynthesis. There are still many remaining questions to be answered, and further 
studies can be performed to see if we can use these biocatalysts to produce biologically active 
pharmaceutical products. The bicyclo[2.2.2]diazaoctanes are an incredibly rich source of 
interesting chemistry, and the potential for large findings still remains fairly untapped. We look 
forward to the continued investigation of notoamide, malbrancheamide, and paraherquamide 
gene products towards the development of novel biocatalysts, understanding of biosynthetic 
chemistry, and identification of new natural products with improved biological activities. We are 
also further expanding the breadth of fungal indole alkaloids with the inclusion of the citrinalin 
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and roquefortine compounds,
152,153
 and look forward to the beginning of our investigations of 
those gene clusters as well. 
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